Clinical trial register · France

Clinical Trials in Bordeaux, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9697 matching records held by the registry are in this view. Synced 26 Oct 2026, 03:20 UTC

9697

Studies in scope

all four open statuses

6025

Recruiting now

open to new participants

1033

Lead sponsors

across recruiting studies

Top sites

Paris 2821 Lyon 1392 Bordeaux 1389 Marseille 1285 Lille 1282

Trials with a site in Bordeaux

Status

Study

Lead sponsor

Phase

Enrol

Sites in France

Start

Active, closed

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer

DrugsS095029·Keytruda·Pembrolizumab

Servier Bio-Innovation LLC

Phase 1/2

Bordeaux, Dijon, Lille, Saint-Cloud, Saint-Herblain, Vandœuvre-lès-Nancy

2024-08-31

Active, closed

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

NCT06503731Antibody-mediated Rejection

argenx

Phase 2

Bordeaux, La Tronche, Toulouse

2024-08-30

Active, closed

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142Immunoglobulin A Nephropathy

DrugPovetacicept

Alpine Immune Sciences Inc, A Subsidiary of Vertex

Phase 3

605

Bordeaux, Créteil, Le Puy-en-Velay, Marseille, Nantes, Paris, Saint-Priest-en-Jarez, Valenciennes

2024-08-30

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

444

La Tronche, Pierre-Bénite, Brest, Mulhouse, Lille, Bordeaux, Limoges, Rouen

2024-08-28

Recruiting

Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes

NCT06111950Taybi Linder Syndrome, Microcephalic Osteodysplastic Primordial Dwarfism Types I and III, Roifman Syndrome, Lowry Wood Syndrome

Hospices Civils de Lyon

Not applicable

Bordeaux, Bron, Dijon, Lille, Paris, Rennes

2024-08-27

Recruiting

Evaluating the Safety and Efficacy of the "HIFU" High-intensity Focused Ultrasound Treatment of Benign Prostatic Hyperplasia;

NCT06601179Benign Prostatic Hyperplasia

EDAP TMS S.A.

Not applicable

100

Besançon, Bordeaux, Lille, Lyon, Martigues, Suresnes, Toulon, Toulouse

2024-08-23

Recruiting

Dural Sinus Stenting of Low Grade Dural Arteriovenous Fistulae (DAVF) for Pulsatile Tinnitus Treatment

NCT05679271Pulsatile Tinnitus

University Hospital, Bordeaux

Not applicable

Bordeaux

2024-08-22

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

699

Toulouse, Vandœuvre-lès-Nancy, Bordeaux, Nantes, Clermont-Ferrand, Amiens, Paris, Argenteuil

2024-08-19

Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma

DrugZilovertamab vedotin

Merck Sharp & Dohme LLC

Phase 1/2

Bordeaux, Lyon, Nantes, Marseille, Villejuif

2024-08-16

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

Bordeaux, Caen, Dijon, Le Mans, Lille, Marseille, Montpellier, Strasbourg

2024-08-13

Active, closed

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

NCT06531109Alopecia Areata

DrugRitlecitinib

Pfizer

Observational

450

Bordeaux, Argenteuil, Caen, Dijon, La Tronche, Lille, Rennes, Rouen

2024-08-07

Recruiting

Decompression of Pudendal and Inferior Cluneal Nerves Using Robot-assisted Laparoscopy for Entrapment Neuralgias : the X-DECO Study

NCT06578767Pudendal Neuralgia

UBOSGA

Observational

200

Bordeaux

2024-07-31

Active, closed

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

NCT06440967Hot Flashes

DrugsFezolinetant·Tamoxifen

Astellas Pharma Global Development, Inc.

Phase 3

982

Angers, Bayonne, Bordeaux, Caen, Dijon, Le Mans, Lille, Lyon

2024-07-31

Recruiting

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

NCT05373264ADPKD

DrugHydrochlorothiazide

University Medical Center Groningen

Phase 3

300

Bordeaux, Brest, Lyon, Nancy, Paris

2024-07-31

Active, closed

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816Geographic Atrophy

DrugVonaprument

Annexon, Inc.

Phase 3

659

Bordeaux, Créteil, Dijon, Écully, Marseille, Nice, Paris, Strasbourg

2024-07-30

Recruiting

Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

NCT06476184Ovarian Cancer

DrugsPaclitaxel·Carboplatin

ARCAGY/ GINECO GROUP

Phase 3

250

Angers, Avignon, Bayonne, Besançon, Bordeaux, Brest, Caen, Chambray-lès-Tours

2024-07-30

Active, closed

A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer

NCT07192588Radiodermatitis; Acute

Graegis Pharmaceuticals Ltd

Phase 2

273

Bordeaux, Lyon, Villejuif

2024-07-26

Recruiting

Drowning-related Acute Respiratory Failure

NCT06183827Drowning

Assistance Publique Hopitaux De Marseille

Not applicable

210

Bayonne, Bordeaux, La Rochelle, Les Sables-d'Olonne, Marseille, Montpellier, Nantes, Nice

2024-07-24

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

Bordeaux, Lyon Cedex08, Clermont-Ferrand, Strasbourg, Marseille, Plérin, Besançon, Toulouse

2024-07-24

Active, closed

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531Progressive Supranuclear Palsy

Ferrer Internacional S.A.

Phase 2

241

Bordeaux, Marseille, Nîmes, Paris, Toulouse

2024-07-23

Recruiting

Prospective Cohort Study of Neurogenetic Diseases

NCT06048523Genetic Disease, Nervous System Diseases

University Hospital, Bordeaux

Not applicable

150

Bordeaux

2024-07-18

Recruiting

Personalized Medicine for Advanced Biliary Cancer Patients

NCT05615818Biliary Tract Neoplasms

DrugsFutibatinib·Neratinib·Zanidatamab·Binimetinib

UNICANCER

Phase 3

800

Amiens, Angers, Avignon, Besançon, Bordeaux, Caen, Clermont-Ferrand, Créteil

2024-07-18

Active, closed

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

NCT06456580Generalized Myasthenia Gravis

DrugTelitacicept

Vor Biopharma

Phase 3

191

Nice, Bordeaux

2024-07-17

Active, closed

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441Resectable Non-small Cell Lung Cancer

DrugsFianlimab·Cemiplimab·Paraplatin·Taxol

Regeneron Pharmaceuticals

Phase 2

195

Nancy, Saint-Herblain, Bordeaux, Limoges, Boulogne-Billancourt, Dijon, Nantes, Vantoux

2024-07-16

Recruiting

COmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial

NCT06425614On-pump Cardiac Surgery, High Risk for Bleeding, Autotransfusion

University Hospital, Bordeaux

Not applicable

570

Bordeaux, Bron, Montpellier, Nantes, Paris, Rennes, Strasbourg, Toulouse

2024-07-15

Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

NCT06264180Advanced Melanoma

DrugsVusolimogene Oderparepvec·Relatlimab·Opdivo·Nivolumab

Replimune, Inc.

Phase 3

400

Bordeaux, Lille, Marseille, Nice, Paris, Pierre-Bénite, Villejuif

2024-07-11

Active, closed

Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma

NCT05901194Hepatocellular Carcinoma Non-resectable

DrugLenvatinib

Assistance Publique - Hôpitaux de Paris

Phase 1/2

Bordeaux, Créteil, Lille, Rennes, Tours, Villejuif

2024-07-10

Recruiting

Diagnosis of Respiratory Disorders by the Numerical Modeling.

NCT06670261Nasal Obstruction, Deviated Nasal Septum

University Hospital, Bordeaux

Observational

300

Bordeaux

2024-07-09

Recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

DrugIvosidenib

Servier Bio-Innovation LLC

Phase 3

136

Bordeaux, Lille, Lyon, Marseille, Paris, Saint-Herblain, Strasbourg, Toulouse

2024-07-09

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744Juvenile Psoriatic Arthritis

DrugsSkyrizi·Risankizumab·Adalimumab

AbbVie

Phase 3

Bordeaux, Le Kremlin-Bicêtre

2024-07-08

Recruiting

Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma

NCT06468176Glioma, Malignant

Institut du Cancer de Montpellier - Val d'Aurelle

Not applicable

187

Montpellier, Amiens, Bordeaux, Lyon, Marseille, Nancy, Nîmes, Toulouse

2024-07-05

Recruiting

Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer

NCT06582628Metastatic Prostate Cancer

DrugEnzalutamide

Fundacion Oncosur

Phase 2

Bordeaux, Brest, Lille, Paris, Strasbourg, Villejuif

2024-07-05

Recruiting

Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation

NCT07777744Ventricular Tachycardia (VT), Premature Ventricular Complexes

University Hospital, Basel, Switzerland

Observational

15,000

Bordeaux, Chambray-lès-Tours, Poitiers, Toulouse

2024-07-01

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6

Boehringer Ingelheim

Phase 1/2

768

Bordeaux, Caen, Lyon, Marseille, Paris, Rennes, Saint-Herblain, Strasbourg

2024-06-28

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Bordeaux, Brest, Le Mans, Lille, Lyon, Marseille, Montpellier, Nice

2024-06-25

Active, closed

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129Large B-cell Lymphoma

DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone

Celgene

Phase 3

850

Nice, Strasbourg, Bordeaux, Pessac, Marseille, Dijon, Besançon, Brest

2024-06-19

Recruiting

A Randomised Clinical Investigation to Assess Efficacy of Low Volume Transanal Irrigation by Qufora® IrriSedo MiniGo Versus Conservative Treatment for Low Anterior Resection Syndrome Patients

NCT06923150Gastroenterology, LARS - Low Anterior Resection Syndrome, Rectal Cancer

Qufora A/S

Observational

Amiens, Besançon, Bordeaux, La Tronche, Marseille, Nantes, Pessac, Pierre-Bénite

2024-06-18

Active, closed

Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation

NCT06444087Hidradenitis Suppurativa

Novartis Pharmaceuticals

Observational

192

Nice, Antony, Bordeaux, Brest, Calais, Dijon, La Rochelle, Le Mans

2024-06-17

Recruiting

National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis

NCT06356831Endometriosis, Cryotherapy Effect, Surgical, Radiology

Centre Hospitalier Intercommunal Creteil

Observational

300

Bordeau, Bordeaux, Clermont-Ferrand, Créteil, Lyon, Marseille, Montpellier, Nîmes

2024-06-15

Active, closed

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

NCT06284122Follicular Lymphoma

DrugsBendamustin·Mosunetuzumab·Vincrystine·Obinutuzumab

The Lymphoma Academic Research Organisation

Phase 3

790

Avignon, Bayonne, Besançon, Bordeaux, Cahors, Chambéry, Clermont-Ferrand, Créteil

2024-06-07

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

Marseille, Bordeaux, Rennes, Saint Priest En Jarez, Lyon, Le Mans, Villejuif, Dijon

2024-06-07

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Bordeaux, Brest, Créteil, Le Mans, Lyon, Marseille, Montpellier, Paris

2024-06-05

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06507306Solid Tumor, Adult

DrugsKQB198·Tagrisso·Amivantamab·Osimertinib

Kumquat Biosciences Inc.

Phase 1

Marseille, Saint-Herblain, Bordeaux, Toulouse, Nantes

2024-06-03

Active, closed

Outcomes of Arterial Allografts Preserved at +2 to +8°C for Revascularization in Septic Settings

NCT06963255Revascularization in a Septic or Potentially Septic Environment

Hospices Civils de Lyon

Observational

Bordeaux, Bron

2024-06-03

Not yet open

Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)

NCT03454646Alzheimer Disease, Cholinesterase Inhibitors

University Hospital, Bordeaux

Phase 4

1,205

Amiens, Angers, Bastia, Besançon, Bordeaux, Brest, Bron, Caen

2024-06-01

Active, closed

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel

Amgen

Phase 1

120

Bordeaux, Dijon, Marseille, Villejuif

2024-05-29

Recruiting

Rein 3D PRINT PERSONALIZE

NCT06379698Tumoral Kidney

University Hospital, Bordeaux

Not applicable

Bordeaux

2024-05-28

Recruiting

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

NCT06195709Breast Carcinoma

Institut Curie

Phase 3

300

Bayonne, Bordeaux, Caen, Dijon, Lille, Limoges, Lyon, Marseille

2024-05-27

Active, closed

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

NCT05735834Splenic Marginal Zone Lymphoma

DrugsTruxima·Zanubrutinib·Rituximab

International Extranodal Lymphoma Study Group (IELSG)

Phase 3

122

Bordeaux, Grenoble, Paris, Pierre-Bénite, Vandœuvre-lès-Nancy

2024-05-21

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Avignon, Bordeaux, Créteil, Lille, Limoges, Lyon, Marseille, Montpellier

2024-05-21

Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386Prostatic Neoplasms, Castration-Resistant

DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere

Merck Sharp & Dohme LLC

Phase 1/2

220

Bordeaux, Strasbourg, Paris, Villejuif

2024-05-20

Recruiting

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

NCT06414954Myasthenia Gravis, Myasthenia Gravis, MuSK

NMD Pharma A/S

Phase 2

Bordeaux, Marseille, Nantes, Nice

2024-05-16

Recruiting

Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves

NCT06181357COPD

University Hospital, Limoges

Not applicable

244

Bordeaux, Brest, Bron, Dijon, Grenoble, Lille, Limoges, Marseille

2024-05-06

Active, closed

Vitiligo Treatment by Targeting TYK2 Mediated Responses

NCT06327321Vitiligo, Generalized

DrugDeucravacitinib

Centre Hospitalier Universitaire de Nice

Phase 2

128

Nice, Paris, Bordeaux, Lille, Lyon

2024-05-05

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

473

Bordeaux, Lyon, Caen, Toulouse, Lille, Rennes, Poitiers, Paris

2024-05-03

Recruiting

Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections

NCT05902221Infections Joint Prosthetic

DrugsRifampicin·Moxifloxacin·Amoxicillin

Centre Hospitalier Universitaire de Nice

Phase 3

235

Annecy, Bordeaux, Boulogne, Lyon, Marseille, Montpellier, Nantes, Nice

2024-05-02

Not yet open

Leukocyte- and Platelet-Rich Fibrin in the Surgical Treatment of Medication-related Osteonecrosis of the Jaw

NCT06419010Osteonecrosis of the Jaw

University Hospital, Toulouse

Not applicable

150

Bordeaux, Limoges, Montpellier, Paris, Toulouse

2024-05

Active, closed

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

DrugRetatrutide

Eli Lilly and Company

Phase 3

10,000

Bois-Guillaume, Bordeaux, Clermont-Ferrand, Corbeil-Essonnes, La Tronche, Le Coudray, Montpellier, Nantes

2024-04-30

Active, closed

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

NCT06188702MTAP-deleted Solid Tumors

DrugTNG462

Servier Bio-Innovation LLC

Phase 1/2

Bordeaux, Dijon

2024-04-29

Active, closed

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

NCT06346067Advanced or Metastatic NRAS-mutant Melanoma

DrugsNaporafenib·Temodar·Dacarbazine·Trametinib

Erasca, Inc.

Phase 3

Bordeaux, Dijon, Le Mans, Lille, Lyon, Marseille, Paris, Villejuif

2024-04-29

Recruiting

Study of REM-422 in Patients With AML or Higher Risk MDS

NCT06297941Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory

DrugREM-422

Remix Therapeutics

Phase 1

100

Bordeaux, Paris, Toulouse, Villejuif

2024-04-26

Active, closed

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

NCT05972551Osteogenesis Imperfecta

DrugRomosozumab

Amgen

Phase 3

111

Bordeaux, Lille, Paris

2024-04-22

Recruiting

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

NCT05980806Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia

DrugsMomelotinib·Pacritinib·Selinexor·Ruxolitinib

Karyopharm Therapeutics Inc

Phase 2

Bordeaux, Pierre-Bénite, Tours, Nîmes, Angers, Paris, Saint-Priest-en-Jarez

2024-04-22

Recruiting

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

NCT06253611Gastric Cancer

DrugsEXL01·Folfox·Fluorouracil·Leucovorin

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2

120

Angers, Avignon, Besançon, Bordeaux, Brest, Caen, Cholet, Clermont-Ferrand

2024-04-16

Active, closed

Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran

NCT05873868Transthyretin Amyloidosis, Amyloidosis, Hereditary

Rennes University Hospital

Observational

Bordeaux, Créteil, Grenoble, Nancy, Toulouse

2024-04-12

Recruiting

CARE1 Pragmatic Clinical Trial

NCT06364631Metastatic Kidney Cancer, Metastatic Kidney Carcinoma

DrugsAxitinib·Cabozantinib·Yervoy·Ipilimumab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

1,250

Angers, Avignon, Bayonne, Besançon, Bordeaux, Caen, Chalon-sur-Saône, Clermont-Ferrand

2024-04-12

Recruiting

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064Recurrent or Metastatic Solid Tumors

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 1/2

680

Dijon, Bordeaux, Montpellier, Rennes, Saint-Herblain, Paris, Lyon, Villejuif

2024-04-10

Recruiting

Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT06291025Thrombotic Microangiopathies

University Hospital, Rouen

Not applicable

131

Amiens, Angers, Besançon, Bobigny, Bondy, Bordeaux, Clermont-Ferrand, Lille

2024-04-10

Recruiting

Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction (PROBIN)

NCT05674487Fetal Growth Restriction

DrugMisoprostol

University Hospital, Bordeaux

Not applicable

774

Bordeaux

2024-04-09

Active, closed

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408Sjögren's Syndrome (SS)

DrugDazodalibep

Amgen

Phase 3

434

Bordeaux, Brest, Mulhouse, Paris, Strasbourg

2024-04-08

Recruiting

Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma

NCT06430424Relapsed Cancer, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

University Hospital, Bordeaux

Observational

Bordeaux

2024-04-05

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

2,554

Amiens, Annonay, Bois-Guillaume, Bordeaux, Boulogne-Billancourt, Brest, Clermont-Ferrand, La Roche-sur-Yon

2024-03-29

Recruiting

A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

NCT06163430Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia

DrugHS-10382

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2

330

Lyon, Bordeaux, Marseille, Nantes, Paris, Pierre-Bénite

2024-03-26

Recruiting

Efficacy Investigation of the Medical Device Apneal® on Smartphone for Sleep Apnea-Hypopnea Syndrome Diagnosis

NCT06578390Sleep Apnea Syndromes

Mitral

Not applicable

500

Aix-en-Provence, Antony, Bordeaux, Montpellier, Mulhouse, Paris, Reims, Roanne

2024-03-26

Recruiting

Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype

NCT06269900Hospital Acquired Pneumonia

DrugDexamethasone

Nantes University Hospital

Phase 3

450

Amiens, Angers, Bordeaux, Brest, Caen, Clermont-Ferrand, Clichy, Garches

2024-03-26

Recruiting

Bougie Versus Endotracheal Tube Alone on First-attempt Intubation Success in Prehospital Emergency Intubation (BETA Trial)

NCT06307392Acute Respiratory Failure Requiring Intubation

Nantes University Hospital

Not applicable

710

Nantes, Besançon, Bordeaux, Clermont-Ferrand, La Roche-sur-Yon, Lorient, Lyon, Nancy

2024-03-26

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

100

Bordeaux, Bron, Le Kremlin-Bicêtre, Lille, Toulouse

2024-03-14

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

Hoffmann-La Roche

Phase 3

1,350

Amiens, Angers, Bordeaux, Clichy, Lille, Limoges, Lyon, Montpellier

2024-03-13

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414Oligometastatic Prostate Cancer (OMPC)

DrugsPiflufolastat·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

450

Saint-Cloud, Bordeaux, Bron, Clermont-Ferrand, Rouen, Saint-Herblain

2024-03-12

Recruiting

Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children

NCT05997979Neuropathic Pain, Chronic Pain

DrugCapsaicin

University Hospital, Brest

Phase 3

Amiens, Angers, Bordeaux, Brest, Lyon, Marseille, Montpellier, Tours

2024-03-05

By invitation

Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy

NCT06138743Myotonic Dystrophy 1

Sarepta Therapeutics, Inc.

Phase 1/2

Angers, Bordeaux, Lille, Nice, Paris

2024-03-04

Recruiting

Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting

NCT06081400Desmoid Tumor

University Hospital, Strasbourg, France

Not applicable

150

Besançon, Bordeaux, Caen, Dijon, Lyon, Marseille, Nantes, Nice

2024-03-04

Active, closed

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118Dermatitis Atopic

DrugsPimecrolimus·Amlitelimab·Tacrolimus

Sanofi

Phase 3

464

Bordeaux, Clermont-Ferrand, Créteil, Lille, Paris, Rouen, Saint-Pierre

2024-02-29

Recruiting

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT05935215Atypical Hemolytic Uremic Syndrome

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Bordeaux, Paris, Rouen, Toulouse, Tours

2024-02-28

Recruiting

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

NCT06239311Moderate to Severe Atopic Dermatitis

DrugMethotrexate

medac GmbH

Phase 3

277

Bordeaux, Clermont-Ferrand, Nantes, Pierre-Bénite

2024-02-27

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Bordeaux, Caen, Clermont-Ferrand, Dijon, Lyon, Marseille, Montpellier, Nantes

2024-02-27

Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

740

Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy

2024-02-26

Recruiting

SNV1521 in Participants With Advanced Solid Tumors

NCT06220864Advanced Solid Tumor

DrugsDB-1310·Abiraterone·Darolutamide

ParVation Therapeutics, Inc.

Phase 1

400

Bordeaux, Lyon, Villejuif

2024-02-23

Active, closed

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

NCT06282159Myasthenia Gravis, Generalized

DrugClaseprubart

Dianthus Therapeutics

Phase 2

Bordeaux, Nice, Strasbourg

2024-02-23

Recruiting

Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.

NCT05597540Pyelonephritis Acute, Kidney Transplant Infection

Assistance Publique - Hôpitaux de Paris

Phase 3

470

Bordeaux, Boulogne-Billancourt, Créteil, Lyon, Nantes, Paris, Toulouse

2024-02-22

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05979311HIV, HIV Infections

DrugsBictegravir·Dolutegravir·Emtricitabine·Lamivudine

ViiV Healthcare

Phase 3

463

Bordeaux, Lyon, Montpellier, Nice, Nîmes, Paris

2024-02-21

Recruiting

Radiofrequency Ablation vs Doppler-guided Haemorrhoidal Artery Ligation in the Treatment of Haemorrhoidal Disease

NCT06170736Haemorrhoids, Internal Haemorrhoids, Grade II/III Haemorrhoids

Centre Hospitalier Departemental Vendee

Not applicable

168

Amiens, Angers, Bordeaux, Brest, Écully, La Roche-sur-Yon, Lille, Limoges

2024-02-21

Recruiting

Treatment Resistant Depression and Vagus Nerve Stimulation

NCT05952674Treatment Resistant Depression (TRD)

Assistance Publique - Hôpitaux de Paris

Not applicable

166

Angers, Bordeaux, Caen, Clermont-Ferrand, Colombes, Créteil, Dijon, Grenoble

2024-02-19

Active, closed

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096Delayed Graft Function

DrugEmpasiprubart

argenx

Phase 2

103

Bordeaux, Créteil, La Tronche, Paris, Toulouse, Tours

2024-02-17

Active, closed

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

NCT06077500Small Cell Lung Carcinoma (SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 1

Bordeaux, Bron, Strasbourg, Villejuif

2024-02-14

Recruiting

A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

NCT06078553Congenital Myasthenic Syndrome

argenx

Observational

100

Bordeaux, Bron, Lille, Marseille, Paris, Strasbourg

2024-02-13

Recruiting

Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer

NCT06027632Breast Cancer, Cognitive Dysfunction

Centre Francois Baclesse

Not applicable

300

Bordeaux, Briis-sous-Forges, Caen, Chambéry, Clermont-Ferrand, Dijon, Grenoble, Limoges

2024-02-09

Recruiting

Addiction & Stroke

NCT06187025Stroke

University Hospital, Bordeaux

Not applicable

300

Bordeaux

2024-02-07

Recruiting

Evaluation of Integrated Versus Parallel Connection for Renal Replacement Therapy in ECMO Patients

NCT06038162Venoarterial Extracorporeal Membrane Oxygenation, Renal Replacement Therapy, Acute Kidney Injury

Hospices Civils de Lyon

Not applicable

158

Bordeaux, Clermont-Ferrand, Dijon, Grenoble, Lille, Lyon, Montpellier, Paris

2024-02-07

Recruiting

Oscillatory Activity in Basal Ganglia Circuits During Normal and Pathological Movement

NCT06241924Parkinson Disease, Epilepsy

University Hospital, Bordeaux

Not applicable

Bordeaux

2024-02-05

Recruiting

ESCAPE : Evaluation of Spinal Conservation by Endoscopic Procedures to Avoid Fusion

NCT06950853Spinal Stenosis, Spondylolisthesis

University Hospital, Bordeaux

Observational

375

Bordeaux, Bruges, Lille, Lyon, Marseille, Narbonne, Osny, Pessac

2024-02-01

Recruiting

Mitochondrial Disease-associated ImmunoDeficiencies

NCT06213103Mitochondrial Disorders

University Hospital, Bordeaux

Observational

Bordeaux, Toulouse

2024-01-30

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

617

Bordeaux, Brest, Dijon, Le Mans, Lyon, Marseille, Nantes, Nice

2024-01-30

Recruiting

Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer

NCT05874492Fibrosis, Breast Cancer, Head and Neck Cancer

Association Francaise pour la Recherche Thermale

Not applicable

110

Bordeaux, Créteil, Dijon, Grenoble, Levallois-Perret, Marseille, Mougins, Rennes

2024-01-29

Active, closed

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06225596Metastatic Urothelial Cancer

DrugsZelenectide pevedotin·Avelumab·Gemcitabine·Cisplatin

BicycleTx Limited

Phase 2

375

Besançon, Bordeaux, Le Mans, Pierre-Bénite, Villejuif

2024-01-24

Recruiting

DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study

NCT06059495Adenocarcinoma - GEJ, Gastric Adenocarcinoma

DrugDostarlimab

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2

Besançon, Bordeaux, Brest, Créteil, Lille, Lyon, Marseille, Montpellier

2024-01-22

Recruiting

Contribution of Fast-ripples to the Improvement of the Neurosurgical Management of Drug-refractory Epilepsy

NCT06105645Epilepsy

University Hospital, Toulouse

Not applicable

440

Amiens, Bordeaux, La Tronche, Le Kremlin-Bicêtre, Lille, Lyon, Nancy, Paris

2024-01-19

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Marseille, La Rochelle, Besançon, Nîmes, Bordeaux, Toulouse, Limoges, Montpellier

2024-01-18

Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed

Revolution Medicines, Inc.

Phase 1/2

616

Bron, Dijon, Lille, Nantes, Bordeaux, Angers, Boulogne, Caen

2024-01-18

Recruiting

Ecological Momentary Assessment in Patients With Restless Legs Syndrome

NCT05695963Restless Legs Syndrome

University Hospital, Bordeaux

Not applicable

Bordeaux

2024-01-15

Recruiting

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

NCT06247826Non-small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation

Groupe Francais De Pneumo-Cancerologie

Not applicable

Bordeaux, Brest, Créteil, Dijon, Grenoble, Le Mans, Marseille, Nice

2024-01-15

Recruiting

EWALL-PH OBSERVARTORY 2022

NCT07684131Acute Lymphoblastic Leukemia

Versailles Hospital

Observational

100

Amiens, Angers, Bayonne, Bordeaux, Clamart, Clermont-Ferrand, Corbeil-Essonnes, Grenoble

2024-01-15

Recruiting

TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)

NCT06924099Glioblastoma

NovoCure Ltd.

Observational

430

Amiens, Avignon, Bordeaux, Brest, Bron, Caen, Clermont-Ferrand, Dijon

2024-01-11

Recruiting

Impact of Continuous Positive Airway Pressure on the Occurrence of Acute Exacerbations of COPD in Patients With COPD-OSA Overlap Syndrome (CO-OS)

NCT05958563Sleep Apnea, COPD Exacerbation, Overlap Syndrome

University Hospital, Angers

Not applicable

500

Angers, Bordeaux, Brest, Créteil, Dijon, Grenoble, Le Mans, Nancy

2024-01-09

Recruiting

ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

NCT05787197Metastatic Colorectal Cancer, Circulating Tumor DNA

GERCOR - Multidisciplinary Oncology Cooperative Group

Observational

232

Besançon, Bordeaux, Lille, Lyon, Paris, Pessac, Poitiers, Rouen

2024-01-09

Active, closed

Study of the Conditions of the Effects of Health Mediation on Underserved Population

NCT06180746Mediation

University Hospital, Bordeaux

Observational

1,041

Bordeaux

2024-01-01

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma

DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Truxima

Bristol-Myers Squibb

Phase 1/2

460

Bordeaux, Lyon, Lille, Villejuif, Créteil, Montpellier, Paris, Toulouse

2023-12-29

Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

DrugsOdronextamab·Lenalidomide·Rituximab

Regeneron Pharmaceuticals

Phase 3

580

Marseille, Rennes, Tours, Bordeaux, Pessac, Lille, Rouen, Nantes

2023-12-28

Active, closed

Affera Global Registry

NCT06026345Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

540

Bordeaux, Saint-Priest-en-Jarez, Toulouse

2023-12-22

Active, closed

Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France

NCT06157086Multiple Sclerosis (MS)

Novartis Pharmaceuticals

Observational

302

Angers, Paris, Agen, Altkirch, Amiens, Belfort, Bordeaux, Boulogne-sur-Mer

2023-12-21

Recruiting

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

NCT05581121Cervical Carcinoma, Adenocarcinoma, Adenosquamous Carcinoma

Institut Claudius Regaud

Phase 3

510

Angers, Bordeaux, Brest, Caen, Créteil, Dijon, Lille, Limoges

2023-12-20

Active, closed

Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents

NCT05953389Autism Spectrum Disorder

DrugPitolisant

Bioprojet

Phase 2

Bordeaux, Nantes, Sotteville-lès-Rouen

2023-12-20

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Nice, Bordeaux, Toulouse, Créteil, Lyon

2023-12-19

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Bordeaux, Lyon Cedex08, Strasbourg, Brest, Quint-Fonsegrives, Lille, Suresnes, Clermont-Ferrand

2023-12-18

Recruiting

New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.

NCT06048510Macrosomia, Fetal, Gestational Diabetes Mellitus in Pregnancy

University Hospital, Bordeaux

Not applicable

800

Bordeaux

2023-12-18

Recruiting

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

NCT05800275Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer

DrugsTucatinib·Trastuzumab·Capecitabine

UNICANCER

Phase 2

Bordeaux, Caen, Clermont-Ferrand, Dijon, Lyon, Montpellier, Nice, Reims

2023-12-18

Recruiting

Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)

NCT06022328Myeloproliferative Neoplasm

University Hospital, Bordeaux

Observational

120

Bordeaux

2023-12-15

Recruiting

Low Stable Pressure Pneumoperitoneum in Colorectal Surgery (CROSS STUDY)

NCT06154785Colorectal Surgery, Benign or Malignant Rectal or Colon Tumors

Bordeaux Colorectal Institute Academy

Observational

300

Besançon, Bordeaux, La Tronche, Le Kremlin-Bicêtre, Marseille, Neuilly-sur-Seine, Paris, Pierre-Bénite

2023-12-15

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Avignon, Bordeaux, Le Mans, Lyon, Nice, Saint-Herblain, Toulouse, Villejuif

2023-12-14

Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan

Regeneron Pharmaceuticals

Phase 3

904

Quimper, Rennes, Tours, Bordeaux, Pessac, Poitiers, Lille, Nantes

2023-12-13

Active, closed

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT05734105GIST

DrugsRipretinib·Sutent·Sunitinib

Deciphera Pharmaceuticals, LLC

Phase 3

Dijon, Rennes, Bordeaux, Lyon, Villejuif

2023-12-13

Recruiting

Azathioprine in MOGAD

NCT05349006Central Nervous System Inflammation, MOG-IgG Associated Disease

DrugAzathioprine

Hospices Civils de Lyon

Phase 3

126

Bordeaux, Lille, Lyon, Marseille, Montpellier, Nancy, Nice, Nîmes

2023-12-12

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

110

Tours, Bordeaux, Toulouse, Bron, Paris

2023-12-11

Recruiting

Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation

NCT05983991GATA2 Gene Mutation

Institut Claudius Regaud

Not applicable

150

Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille, Lyon

2023-12-07

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

Bordeaux, Lyon Cedex08, Chambray-lès-Tours, Plérin, Besançon, Toulouse, Lille, Montpellier

2023-12-06

Recruiting

Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery

NCT06246136Open Angle Glaucoma

Elios Vision, Inc.

Not applicable

194

Avranches, Bordeaux, Paris

2023-12-05

Recruiting

Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group

NCT05754593Multiple Sclerosis

University Hospital, Bordeaux

Not applicable

160

Bordeaux

2023-12-04

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer

DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant

BeOne Medicines

Phase 1

433

Bordeaux, Caen, Lille, Marseille, Paris, Rennes, Saint-Herblain, Villejuif

2023-12-01

Recruiting

Deep Learning for Histopathological Classification and Prognostication of Gynaecologic Smooth Muscle Tumours

NCT06540846Stump

Institut Bergonié

Observational

392

Bordeaux

2023-12-01

Recruiting

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

NCT05872204Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor

DrugsAbemaciclib·Letrozole

Universitaire Ziekenhuizen KU Leuven

Phase 2

100

Strasbourg, Bordeaux, Toulouse, Saint-Herblain, Lyon, Paris

2023-11-30

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Angers, Bordeaux, Brest, Bron, Le Kremlin-Bicêtre, Lille, Limoges, Marseille

2023-11-29

Active, closed

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

NCT06113445NonSegmental Vitiligo

DrugPovorcitinib

Incyte Corporation

Phase 3

467

Bordeaux, Reims, Toulouse

2023-11-29

Recruiting

Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

NCT06083129GVHD

DrugsGrafalon·Thymoglobulin

Assistance Publique - Hôpitaux de Paris

Phase 3

324

Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Créteil

2023-11-28

Recruiting

A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.

NCT06022159Soft Tissue Sarcoma

Institut Claudius Regaud

Phase 2

Bordeaux, Lille, Limoges, Lyon, Montpellier, Paris, Poitiers, Saint-Herblain

2023-11-28

Recruiting

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

NCT05948943Lymphatic Malformations

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2/3

232

Angers, Bordeaux, Bron, Caen, Dijon, Lille, Marseille, Montpellier

2023-11-24

Recruiting

Effects of Transcutaneous Vagus Nerve Stimulation on Emotion Regulation and Executive Functioning in Prader-Willi Syndrome

NCT06720571Prader-Willi Syndrome

University of Bordeaux

Not applicable

Bordeaux, Hendaye, Paris, Toulouse

2023-11-22

Recruiting

Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis

NCT06083584Amyotrophic Lateral Sclerosis

Centre Hospitalier Universitaire de Nīmes

Observational

192

Bordeaux, Clermont-Ferrand, Lyon, Marseille, Montpellier, Nîmes, Toulouse

2023-11-22

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Angers, Bayonne, Bordeaux, Caen, Clermont-Ferrand, Créteil, Lyon, Montpellier

2023-11-21

Active, closed

Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

NCT05856695Small Cell Lung Cancer Extensive Stage

DrugsDurvalumab·Paclitaxel·Carboplatin

Intergroupe Francophone de Cancerologie Thoracique

Phase 2

Abbeville, Amiens, Angers, Besançon, Bordeaux, Boulogne-Billancourt, Caen, Chambéry

2023-11-17

Recruiting

Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

NCT06130787Leukemia,Myeloid, Chronic

University Hospital, Clermont-Ferrand

Not applicable

321

Annecy, Bordeaux, Caen, Clermont-Ferrand, Créteil, Grenoble, Le Puy-en-Velay, Lille

2023-11-17

Recruiting

Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene.

NCT06022016DDX41 Gene Mutation

Institut Claudius Regaud

Not applicable

910

Bordeaux, Limoges, Marseille, Montpellier, Toulouse

2023-11-17

Recruiting

Impact of Bacterial Expression and Immune Response in the Severity of Pertussis

NCT05897879Bordetella Pertussis, Whooping Cough

DrugsNasopharyngeal swab·Blood samples

Institut Pasteur

Not applicable

210

Bordeaux, Colombes, Créteil, Lille, Lyon, Marseille, Nantes, Paris

2023-11-16

Active, closed

CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity

NCT06245772Upper Limb Injury

Ipsen

Observational

113

Bagnères-de-Bigorre, Bar-le-Duc, Besançon, Bordeaux, Bourg-en-Bresse, Brest, Corbie, Dax

2023-11-16

Recruiting

Anatomical-Clinical Base of Adenocarcinoma Pancreatic

NCT06128343Adenocarcinoma, Carcinoma, Neoplasms

University Hospital, Toulouse

Observational

1,500

Béthune, Bordeaux, Lille, Lyon, Montpellier, Pau, Toulouse

2023-11-16

Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

DrugsElironrasib·Cetuximab

Revolution Medicines, Inc.

Phase 1/2

534

Angers, Bordeaux, Bron, Lille, Lyon, Montpellier, Nantes, Strasbourg

2023-11-14

Recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

NCT05658640Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsTrametinib·Cytarabine·Dexamethasone·Cyclophosphamide

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Bordeaux, Lille, Lyon, Marseille, Nantes, Paris

2023-11-14

Recruiting

FIH XON7 in Advanced/Metastatic Solid Tumors

NCT06154291Advanced Solid Tumor, Metastatic Cancer

Xenothera SAS

Phase 1/2

255

Bordeaux, Lyon, Suresnes, Toulouse

2023-11-14

Active, closed

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420Neoplasms, Head and Neck

DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab

GlaxoSmithKline

Phase 2

316

Bordeaux, Caen, Marseille, Paris, Rouen, Villejuif

2023-11-14

Recruiting

Long Term Outcome of Easophageal Atresia : Transmics Profiles in Adolescence

NCT05995171Esophageal Atresia

University Hospital, Lille

Observational

300

Lille, Amiens, Angers, Besançon, Bordeaux, Bron, Caen, Clermont-Ferrand

2023-11-14

Active, closed

Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis

NCT05681442Sepsis

Assistance Publique - Hôpitaux de Paris

Phase 4

600

Argenteuil, Avignon, Bordeaux, Boulogne-Billancourt, Clermont-Ferrand, Clichy, Étampes, La Roche-sur-Yon

2023-11-13

Active, closed

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579Breast Cancer

DrugsGa-NeoB·Lu-NeoB·Ribociclib·Fulvestrant

Novartis Pharmaceuticals

Phase 1

Saint-Cloud, Bordeaux, Saint-Herblain

2023-11-13

Active, closed

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

NCT06075706Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 2

Bordeaux, La Tronche, Lille, Lyon, Marseille, Montpellier, Nantes, Paris

2023-11-13

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588Non-small Cell Lung Cancer (NSCLC)

DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

556

Bordeaux, Lyon Cedex08, Rouen, Paris

2023-11-12

Active, closed

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT06073821CLL

DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

652

Bordeaux, ClermontFerrand, Esseylesnancy, Le Mans, Lille, Lyon, Nantes, Paris

2023-11-11

Active, closed

Permanent Intracranial Stenting for Acute Ischemic Stroke Related to a Refractory Large Vessel Occlusion

NCT06071091Acute Ischemic Stroke

Assistance Publique - Hôpitaux de Paris

Not applicable

346

Amiens, Bordeaux, Créteil, Le Kremlin-Bicêtre, Lille, Montpellier, Nancy, Paris

2023-11-08

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

Bordeaux, Brest, Paris, Rennes, Strasbourg, Toulouse

2023-11-08

Recruiting

Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS

NCT06014112Acute Coronary Syndrome, Continuous Glucose Measurement, Glycemic Variability, Cardiovascular Event

University Hospital, Montpellier

Not applicable

850

Béziers, Bordeaux, Montpellier, Nîmes, Paris, Pau, Toulouse, Vannes

2023-11-06

Active, closed

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907Ulcerative Colitis

DrugUpadacitinib

AbbVie

Phase 3

122

Bordeaux, Bron, Paris, Toulouse

2023-11-06

Recruiting

SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours

NCT05192980Neuroblastoma, Ganglioneuroblastoma, Ganglioneuroma

Institut Curie

Not applicable

600

Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Dijon

2023-11-02

Recruiting

Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.

NCT06700057Prostate Cancer, Metastasis

Institut Bergonié

Observational

Bordeaux

2023-11-01

Recruiting

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

NCT06095089Prostatic Neoplasms

DrugsJNJ-101556143·JNJ-87189401·Lutetium Lu-177 Vipivotide Tetraxetan·Pasritamig

Janssen Research & Development, LLC

Phase 1

355

Bordeaux, Lyon, Villejuif

2023-11-01

Active, closed

A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development

NCT06055725Spasticity as Sequela of Stroke

Ipsen

Observational

1,057

Bordeaux, Caen, Rennes, Saint-Genis-Laval, Saint-Jacques

2023-11-01

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Avignon, Besançon, Bordeaux, Caen, Le Mans, Lille, Lyon, Marseille

2023-10-31

Recruiting

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

NCT06725758Solid Tumours

DrugODM-212

Orion Corporation, Orion Pharma

Phase 1/2

315

Bordeaux, Lille, Villejuif

2023-10-26

Recruiting

Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

NCT05674994Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Fondation Hôpital Saint-Joseph

Phase 3

110

Angers, Besançon, Bobigny, Bordeaux, Caen, Clermont-Ferrand, Créteil, Dijon

2023-10-26

By invitation

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380Kidney Transplant Rejection

DrugsTegoprubart·Tacrolimus

Eledon Pharmaceuticals

Phase 2

132

Bordeaux, Grenoble, Limoges, Toulouse

2023-10-25

Recruiting

DESTINY Breast Respond HER2-(Ultra)Low Europe

NCT05945732Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Observational

2,295

Amiens, Antony, Arras, Avignon, Bayonne, Besançon, Bordeaux, Bourg-en-Bresse

2023-10-24

Active, closed

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277Metastatic Non-small Cell Lung Cancer

DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

895

Angers, Avignon, Bayonne, Bordeaux, Caen, Lille, Limoges, Marseille

2023-10-24

Recruiting

Optimization of the Surgical Care Pathway for Kidney Tumors by Digitizing Perioperative Nursing Coordination (UroCCR 126)

NCT06047600Digitizing Perioperative Nursing Coordination

University Hospital, Bordeaux

Not applicable

1,307

Angers, Bordeaux, Cabestany, Caen, Créteil, Marseille, Mont-de-Marsan, Nantes

2023-10-23

Recruiting

Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT)

NCT05888662Ischemic Cardiomyopathy, Catheter Ablation of Ventricular Tachycardia

Rennes University Hospital

Not applicable

150

Bordeaux, Caen, Clermont-Ferrand, Lille, Lyon, Nantes, Paris, Rennes

2023-10-23

Recruiting

Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy

NCT05840562Chemotherapy-induced Peripheral Neuropathy

DrugsCapsaicin·Duloxetine

Institut Cancerologie de l'Ouest

Phase 3

274

Angers, Bordeaux, Caen, Grenoble, Limoges, Lyon, Nantes, Nice

2023-10-20

Recruiting

Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit

NCT05696093Ventilator Associated Pneumonia

Assistance Publique - Hôpitaux de Paris

Phase 3

628

Amiens, Angers, Béthune, Bobigny, Bordeaux, Boulogne-Billancourt, Cholet, Clermont-Ferrand

2023-10-19

Recruiting

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06067841Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb

Phase 1

140

Bordeaux, Lyon Cedex08, Marseille, Villejuif, Paris

2023-10-18

Recruiting

Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors

NCT05874063Germ Cell Tumor

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

387

Angers, Bayonne, Bordeaux, Brest, Clermont-Ferrand, Grenoble, Lille, Limoges

2023-10-17

Not yet open

Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.

NCT05946486Mental Disorder

University Hospital, Bordeaux

Phase 3

174

Bordeaux, Bron, Clermont-Ferrand, Colombes, Créteil, Le Kremlin-Bicêtre, Montpellier, Strasbourg

2023-10-15

Recruiting

FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy

NCT06185569Breast Cancer

Centre Hospitalier Universitaire de Besancon

Observational

4,500

Besançon, Bordeaux, Paris, Perpignan

2023-10-15

Recruiting

Prevention of Organ Dysfunction and Mortality by Monitoring the Administration of Opioids and Hypnotics in Patients at High Postoperative Risk

NCT05893030Sedation and Analgesia Monitoring

Centre Hospitalier Universitaire de Saint Etienne

Not applicable

1,132

Amiens, Besançon, Bordeaux, Brest, Clermont-Ferrand, Grenoble, Lille, Marseille

2023-10-12

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Nice, Rennes, Bordeaux, Toulouse, Reims, Nantes, Lyon, Brest

2023-10-11

Active, closed

PRostate Olaparib Real World Evidence Study

NCT06031805Metastatic Castration-resistant Prostate Cancer

AstraZeneca

Observational

159

Amiens, Angers, Antony, Argenteuil, Avignon, Besançon, Bordeaux, Challes-les-Eaux

2023-10-11

Recruiting

Validation of a Digitalised Intraoral Protection

NCT05866835Ventilatory Performances of Athletes During the Use of the Intra-oral Protections

University Hospital, Bordeaux

Not applicable

Bordeaux, Paris

2023-10-10

Recruiting

Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment

NCT06033274Tricuspid Regurgitation

Montefiore Medical Center

Observational

800

Toulouse, Lille, Bordeaux

2023-10-05

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Epagny Metz-Tessy, Lille, Lyon

2023-10-05

Recruiting

TRansmural hEaliNg Definition in CroHn's Disease (TRENCH 1)

NCT05903066Crohn Disease

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Observational

210

Amiens, Bordeaux, Boulogne-Billancourt, Clermont-Ferrand, Colombes, Lille, Limoges, Marseille

2023-09-28

Recruiting

NAC- NAFLD And Cushing

NCT05881005Cushing Syndrome, Fatty Liver Disease

University Hospital, Angers

Not applicable

100

Angers, Bordeaux, Brest, Grenoble, Lille, Nantes, Vandœuvre-lès-Nancy

2023-09-28

Active, closed

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT05936359Myeloproliferative Neoplasms

DrugsINCA033989·Ruxolitinib

Incyte Corporation

Phase 1

160

Bordeaux, Nîmes, Paris, Villejuif

2023-09-25

Active, closed

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

412

Pierre-Bénite, Bordeaux, Strasbourg, Villejuif

2023-09-22

Active, closed

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290Leiomyosarcoma

DrugsLurbinectedin·Doxorubicin

PharmaMar

Phase 3

469

Lyon, Besançon, Angers, Nice, Bordeaux, Lille, Limoges, Marseille

2023-09-21

Active, closed

Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

NCT06062537Multiple Myeloma

Intergroupe Francophone du Myelome

Observational

200

Amiens, Annecy, Argenteuil, Bayonne, Besançon, Bordeaux, Brive-la-Gaillarde, Caen

2023-09-19

Recruiting

Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to Nephron-sparing Surgery- Rein 3D Anxiety

NCT06035211Tumoral Kidney

University Hospital, Bordeaux

Not applicable

192

Angers, Bordeaux, Caen, Le Kremlin-Bicêtre, Marseille, Nantes

2023-09-19

Recruiting

Hysteroscopy vs. Endouterine Aspiration in the Management of Trophoblastic Retention

NCT05789940Miscarriage

University Hospital, Montpellier

Not applicable

220

Bordeaux, Montpellier, Nice, Nîmes

2023-09-18

Recruiting

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

NCT05917405Acute Myeloid Leukemia in Remission

DrugsClofarabine·Busulfan·Fludarabine

Nantes University Hospital

Phase 2

302

Nantes, Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand

2023-09-14

Active, closed

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941Sjögren's Syndrome

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

774

Amiens, Bordeaux, Grenoble, Le Havre, Le Kremlin-Bictre, Paris

2023-09-11

Recruiting

Systemic Lupus Erythematosus and Accelerated Aging

NCT05698173Systemic Lupus Erythematosus

DrugBlood sample

University Hospital, Bordeaux

Not applicable

Bordeaux

2023-09-08

Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239Metastatic Breast Cancer

DrugsPhesgo·Inavolisib

Hoffmann-La Roche

Phase 3

230

Avignon, Bayonne, Bordeaux, Dijon, Lille

2023-09-08

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

NCT06047171Glomerulonephritis Rapidly Progressive

DrugsCyclophosphamid·Rituximab

Alentis Therapeutics AG

Phase 2

Boulogne-sur-Mer, Bordeaux, Brest, La Tronche, Marseille, Nantes, Nîmes, Paris

2023-09-07

Recruiting

The ReTAVI Prospective Observational Registry

NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction

Institut für Pharmakologie und Präventive Medizin

Observational

250

Bordeaux, Clermont-Ferrand, Lille, Lyon, Marseille, Massy, Nantes, Paris

2023-09-05

Recruiting

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

NCT06006117Marginal Zone Lymphoma

DrugsMosunetuzumab·Bendamustine·Lenalidomide·Rituximab

The Lymphoma Academic Research Organisation

Phase 3

260

Nancy, Amiens, Avignon, Bayonne, Besançon, Bordeaux, Clermont-Ferrand, Créteil

2023-09-05

Active, closed

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

NCT05884398Metastatic Castrate-sensitive Prostate Cancer

DrugApalutamide

Janssen Research & Development, LLC

Phase 3

420

Bordeaux, Lyon, Paris, Rennes, Villejuif

2023-08-31

Recruiting

Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease

NCT05911802Waldenstrom's Disease, Prognostic Index

French Innovative Leukemia Organisation

Observational

500

Amiens, Angers, Bordeaux, Clermont-Ferrand, Le Mans, Lens, Libourne, Lille

2023-08-11

Active, closed

SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer

NCT05826509Prostate Cancer

Institut Claudius Regaud

Phase 2

240

Angers, Bordeaux, Créteil, Grenoble, Lille, Lyon, Marseille, Paris

2023-08-10

Recruiting

Coroflex® ISAR NEO PMCF Study

NCT05698732Coronary Artery Disease (CAD), Ischemic Heart Disease

Fundación EPIC

Observational

3,000

Aix-en-Provence, Ajaccio, Bordeaux, Caen, Colmar, Lille, Paris, Rouen

2023-08-04

Recruiting

Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy

NCT05944913Soft Tissue Sarcoma

Centre Leon Berard

Not applicable

166

Nantes, Lyon, Angers, Bordeaux, Chambray-lès-Tours, Clermont-Ferrand, Dijon, Lille

2023-08-03

Recruiting

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

NCT05625724ART, Pre-Eclampsia

DrugAspirin

University Hospital, Toulouse

Phase 3

1,164

Angers, Bordeaux, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille, Montpellier

2023-08-02

Recruiting

3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME)

NCT05227092Multiple Sclerosis

University Hospital, Bordeaux

Not applicable

Bordeaux

2023-08-02

Recruiting

Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1

NCT05856565Metastatic Melanoma

Nantes University Hospital

Observational

700

Besançon, Brest, Angers, Blois, Bordeaux, Dijon, Grenoble, La Rochelle

2023-07-24

Recruiting

A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

NCT05639413Metastatic Colorectal Cancer, BRAF V600E Mutation Positive

UNICANCER

Not applicable

400

Avignon, Bayeux, Beauvais, Bordeaux, Bourg-en-Bresse, Cahors, Calais, Caluire-et-Cuire

2023-07-24

Recruiting

Effects of Early Testosterone Gel Administration on Physical Performance in the Critically Ill

NCT05825092Critical Illness

University Hospital, Clermont-Ferrand

Phase 2

600

Bordeaux, Clermont-Ferrand, La Roche-sur-Yon, Nantes

2023-07-21

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Nice, Marseille, Dijon, Besançon, Bordeaux, Rennes, Lille, Pierre-Bénite

2023-07-19

Recruiting

Same Day Ambulatory Appendectomy (SAMBA)

NCT05691348Appendicitis

Centre Hospitalier Universitaire de Nice

Not applicable

1,400

Nice, Bordeaux, Troyes, La Tronche, Lyon, Saint-Priest-en-Jarez, Voiron, Marseille

2023-07-17

Active, closed

ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach

NCT05928416Amyotrophic Lateral Sclerosis, Sporadic, Amyotrophic Lateral Sclerosis

ZIWIG

Observational

653

Strasbourg, Saint-Herblain, Saint-Étienne-de-Montluc, Bron, Angers, Bordeaux, Brest, Caen

2023-07-11

Recruiting

PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years

NCT05387954Cryptogenic Ischemic Stroke, Patent Foramen Ovale

Assistance Publique - Hôpitaux de Paris

Phase 3

792

Amiens, Bayonne, Besançon, Bordeaux, Brest, Bron, Caen, Clermont-Ferrand

2023-07-07

Recruiting

Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

NCT04020263Cardiogenic Shock

DrugLevosimendan

Pr Bruno LEVY

Phase 3

610

Strasbourg, Marseille, Caen, Dijon, Besançon, Nîmes, Bordeaux, Toulouse

2023-07-03

Active, closed

Outpatient Holmium LASER Enucleation of the Prostate: Benefit of MOSES(TM) 2.0 Technology

NCT05768776Benign Prostatic Hypertrophy, Holmium Laser Enucleation of the Prostate

University Hospital, Bordeaux

Observational

200

Bordeaux

2023-06-28

Active, closed

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

DrugsIrinotecan·Pembrolizumab

Novartis Pharmaceuticals

Phase 1

123

Bordeaux, Marseille, Toulouse

2023-06-27

Active, closed

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

NCT05696717Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy

Theravance Biopharma

Phase 3

102

Nîmes, Bordeaux, Toulouse

2023-06-27

Recruiting

Research Biobank From Neuromuscular Biopsy Residues (in the Context of Care)

NCT06074822Neuromuscular Diseases, Muscle, Nerve

University Hospital, Bordeaux

Observational

500

Bordeaux

2023-06-26

Active, closed

Casting Light on HOst-cytomegaloviRUs Interaction in Solid Organ Transplantation

NCT05701228Cytomegalovirus Infections, Solid Organ Transplantation

University Hospital, Bordeaux

Observational

552

Bordeaux, Lyon, Paris, Suresnes, Toulouse, Villejuif

2023-06-26

Active, closed

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

NCT05845814Metastatic Urothelial Carcinoma, Urothelial Neoplasms

DrugsPembrolizumab/Vibostolimab·Pembrolizumab/Favezelimab·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

390

Bordeaux, Dijon, Toulouse, Pierre-Bénite, Paris

2023-06-23

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

Nice, Bordeaux, Reims, Nantes, Lyon, Antony

2023-06-21

Recruiting

Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)

NCT05839717Myeloproliferative Neoplasm

University Hospital, Bordeaux

Observational

120

Angers, Bayonne, Bordeaux, Brest, Dax, Libourne, Mont-de-Marsan, Pessac

2023-06-19

Active, closed

Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma

NCT05830084Ewing Sarcoma

DrugRegorafenib

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1

Bordeaux, Lille, Lyon, Paris, Villejuif

2023-06-16

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501Hematologic Cancer

DrugVenetoclax

AbbVie

Phase 1

135

Bordeaux, Montpellier, Lille, Nantes, Villejuif, Paris

2023-06-09

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

Avignon, Bayonne, Bordeaux, Lyon, Montpellier, Rennes, Toulouse

2023-06-07

Active, closed

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

NCT05888831Advanced Solid Tumors

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 1/2

100

Villejuif, Marseille, Bordeaux

2023-06-06

Active, closed

A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML

NCT05199051AML, Leukaemia (Acute Myeloid)

Centre Antoine Lacassagne

Phase 2

Amiens, Angers, Bordeaux, Caen, Chambéry, Clamart, Limoges, Nancy

2023-06-03

Recruiting

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

NCT05862285Cancer

DrugsTiragolumab and Atezolizumab·Divarasib·Tiragolumab·Ipatasertib

Hoffmann-La Roche

Phase 3

100

Marseille, Bordeaux, Caen, Dijon, Lyon, Montpellier, Nantes, Nîmes

2023-06-01

Recruiting

Pilot Study of Microvesicles in Pre-eclamptic and Non-pre-eclamptic Women With Threatened Preterm Delivery

NCT05675969Pre-Eclampsia

University Hospital, Bordeaux

Not applicable

Bordeaux

2023-05-31

Recruiting

Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies

NCT05772559Acute Myeloid Leukemia, Genetic Predisposition to Disease

Assistance Publique - Hôpitaux de Paris

Observational

500

Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Dijon

2023-05-31

Active, closed

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05809531C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis

DrugPegcetacoplan

Apellis Pharmaceuticals, Inc.

Phase 3

100

Bordeaux, Nantes

2023-05-29

Recruiting

Evaluation of the Evolution of Patient Care Within the Spinal Pathology Department

NCT07627282Spinal Stenosis, SPINAL Fracture, Vertebral Osteomyelitis, Vertebral Metastasis

University Hospital, Bordeaux

Not applicable

15,000

Bordeaux

2023-05-25

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA

DrugInotuzumab Ozogamicin

Pfizer

Phase 2

100

Nice, Strasbourg, Bordeaux, Toulouse, Vandœuvre-lès-Nancy, Lille, Paris, Lyon

2023-05-17

Active, closed

Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus

NCT05825573Intracardiac Thrombus, STEMI, Heart Failure

DrugDirect Anticoagulant

Centre Hospitalier Universitaire de Nīmes

Phase 3

340

Angers, Auxerre, Avignon, Bastia, Bordeaux, Brest, Chartres, Clermont-Ferrand

2023-05-15

Recruiting

OPTImal Treatment of Sinus VENOSUS Defect

NCT05865119Sinus Venosus Defect, Congenital Heart Disease, Sinus Venosus Atrial Septum Defect

Centre Chirurgical Marie Lannelongue

Not applicable

Bordeaux, Bron, Clermont-Ferrand, Grenoble, Le Plessis-Robinson, Lille, Marseille, Nantes

2023-05-12

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Besançon, Bordeaux, Dijon, Lille, Limoges, Loire Atlantique, Lyon, Marseille

2023-05-08

Recruiting

Impact of Procalcitonin-guided Algorithm on Early Discontinuation of Antibiotic Therapy

NCT05350813Bacterial Infections

University Hospital, Toulouse

Not applicable

296

Amiens, Bordeaux, Clermont-Ferrand, Lille, Nantes, Paris, Saint-Denis, Toulouse

2023-05-02

Recruiting

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

NCT05587894COVID-19, Immunodeficiency

DrugsNirmatrevlir/ritonavir·Veklury·Remdesivir

ANRS, Emerging Infectious Diseases

Phase 2

256

Bordeaux, Dijon, Lyon, Montpellier, Nantes, Paris, Reims, Toulouse

2023-04-27

Active, closed

Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

NCT05781308Non Small Cell Lung Cancer

DrugsTecentriq·Avastin·Atezolizumab·Paclitaxel

Intergroupe Francophone de Cancerologie Thoracique

Phase 2

156

Amiens, Angers, Avignon, Bayonne, Besançon, Bordeaux, Boulogne, Caen

2023-04-26

Active, closed

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501Renal Cell Carcinoma

DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda

Hoffmann-La Roche

Phase 2

199

Avignon, Besançon, Bordeaux, Caen, Lyon, Villejuif

2023-04-21

Recruiting

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139Breast Cancer, Solid Tumors, Adult

DrugsTersolisib·Imlunestrant·Tamoxifen·Exemestane

Eli Lilly and Company

Phase 1/2

880

Bordeaux, Lyon, Marseille, Nice, Toulouse, Villejuif

2023-04-17

Active, closed

Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting

NCT05772429Seizures

DrugCannabidiol

Jazz Pharmaceuticals

Observational

158

Amiens, Angers, Bordeaux, Bron, Dijon, Grenoble, Le Kremlin-Bicêtre, Lille

2023-04-17

Recruiting

Modelling of Pharyngeal Laryngeal Effectiveness

NCT06014710Swallowing Disorders

University Hospital, Toulouse

Not applicable

520

Bordeaux, Rouen, Toulouse, Tours

2023-04-14

Active, closed

A Rollover Study of CC-122

NCT05688475Non-Hodgkin Lymphoma

DrugDexamethasone

Bristol-Myers Squibb

Phase 1

Bordeaux, Marseille

2023-04-11

Recruiting

ProActIF-01 Trial: Feasibility Study of an Individualized Program of Nutrition and Adapted Physical Activity in Frail Patients With Advanced Digestive Cancers

NCT05441163CANCER

Institut Curie

Not applicable

Tours, Avignon, Bordeaux, Clermont-Ferrand, Grenoble, Lille, Lyon, Montpellier

2023-04-08

Recruiting

Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia

NCT05641142Hereditary Hemorrhagic Telangiectasia, Rendu Osler Disease

University Hospital, Clermont-Ferrand

Not applicable

100

Angers, Bordeaux, Boulogne-Billancourt, Caen, Clermont-Ferrand, Dijon, Lille, Lyon

2023-04-07

Recruiting

COMpassion for Psychiatric Disorders And Self-Stigma

NCT05698589Bipolar Disorder, Schizophrenia, Depression, Borderline Personality Disorder

University Hospital, Strasbourg, France

Not applicable

336

Bordeaux, Bron, Clermont-Ferrand, Laxou, Montpellier, Reims, Strasbourg

2023-04-03

Recruiting

Evaluation of the Impact of Participation in a Psycho-education Program for Victims of Sexual Violence

NCT06718387Ptsd, Sexual Violence, Therapeutic Alliance

Centre Hospitalier Charles Perrens, Bordeaux

Not applicable

Bordeaux

2023-04-01

Recruiting

NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions

NCT05540288Behavioural Addiction

Nantes University Hospital

Phase 3

266

Besançon, Bordeaux, Brest, Clermont-Ferrand, Dijon, La Rochelle, Lyon, Montpellier

2023-03-31

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05774951Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

4,300

Angers, Argenteuil, Avignon, Bordeaux, Bourg-en-Bresse, Caen, Cholet, Clermont-Ferrand

2023-03-31

Recruiting

Intensive Preoperative Speech Rehabilitation in Drug-Resistant Temporal Epilepsy

NCT05609084Epilepsy, Anomia, Temporal Lobe Epilepsy

Assistance Publique Hopitaux De Marseille

Not applicable

214

Bordeaux, Grenoble, Lille, Lyon, Marseille, Nancy, Paris, Rennes

2023-03-30

Recruiting

Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease

NCT05732727Chronic Kidney Disease(CKD), Uncontrolled Hypertension

University Hospital, Tours

Phase 3

720

Angers, Bordeaux, Brest, Chalon-sur-Saône, Chartres, Clermont-Ferrand, Colmar, Grenoble

2023-03-28

Active, closed

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202Bladder Cancer

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 3

1,135

Bordeaux, Clermont-Ferrand, Grenoble, Limoges, Lyon, Nantes, Nîmes, Orléans

2023-03-23

Recruiting

Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)

NCT05596539Hypophosphatasia

Assistance Publique - Hôpitaux de Paris

Observational

200

Bordeaux, Lille, Lyon, Nice, Paris, Poitiers, Rennes, Saint-Priest-en-Jarez

2023-03-22

Active, closed

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

DrugsELVN-002·Fam-Trastuzumab Deruxtecan-Nxki·Trastuzumab emtansine·Trastuzumab deruxtecan

Enliven Therapeutics

Phase 1

198

Marseille, Rennes, Caen, Bordeaux, Dijon, Lyon, Villejuif

2023-03-20

Recruiting

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

NCT05310591B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse

Assistance Publique - Hôpitaux de Paris

Phase 1/2

Bordeaux, Lille, Lyon, Marseille, Montpellier, Nancy, Nantes, Paris

2023-03-15

Active, closed

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC

NCT05546879Hepatocellular Carcinoma

DrugsNP137·Atezolizumab·Bevacizumab

University Hospital, Grenoble

Phase 1

Grenoble, Angers, Bordeaux, Marseille, Nantes, Paris, Reims, Toulouse

2023-03-15

Recruiting

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

NCT05689151Atopic Dermatitis, Eczema

DrugAbrocitinib

Pfizer

Observational

183

Amiens, Besançon, Bezannes, Bordeaux, Brest, Caen, Calais, Chalon-sur-Saône

2023-03-09

Active, closed

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

14,012

Avignon, Besançon, Béziers, Bobigny, Bordeaux, Caen, Compiègne, Dijon

2023-03-09

Active, closed

EEG Analysis for the Objective Assessment of Drowsiness

NCT05453643Sleep Deprivation

Physip S.A

Not applicable

Bordeaux

2023-03-08

Recruiting

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma

NCT04128072Stage IB-IIB Cutaneous T-Cell Lymphoma

DrugMogamulizumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

Bordeaux, Paris

2023-03-07

Recruiting

Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE)

NCT05521776Preeclampsia (PE)

Assistance Publique - Hôpitaux de Paris

Not applicable

14,500

Angers, Bordeaux, Bron, Clamart, Clermont-Ferrand, Créteil, Dijon, Lille

2023-03-06

Recruiting

Cost-utility of Focal HIFU vs Prostatectomy

NCT05710861Prostate Cancer

University Hospital, Bordeaux

Not applicable

346

Besançon, Bordeaux, Colmar, Grenoble, Guilherand-Granges, Lille, Lyon, Marseille

2023-03-06

Active, closed

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399Melanoma

DrugsPhesgo·Relatlimab·Nivolumab

Bristol-Myers Squibb

Phase 3

579

Toulouse, Chambray-lès-Tours, Lille, Nantes, Villejuif, Amiens, Bayonne, Bordeaux

2023-03-06

Recruiting

Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)

NCT05711173Venous Thromboses, Thromboembolic Disease, Neutrophil Extracellular Trap Formation, Clonal Hematopoiesis of Indeterminate Potential

DrugAdditional blood sampling

University Hospital, Bordeaux

Not applicable

150

Bordeaux, Lille, Marseille

2023-03-03

Recruiting

Efficacy of a Smartphone App. Designed to Manage Craving & Individual Predictors of Substance Use/Addictive Behavior

NCT04732676Addiction

Centre Hospitalier Charles Perrens, Bordeaux

Not applicable

274

Bordeaux

2023-03-01

Active, closed

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

NCT05593614Chemotherapy-induced Peripheral Neuropathy

AlgoTherapeutix

Phase 2

276

Bayonne, Bordeaux, Montpellier, Paris, Poitiers, Reims, Strasbourg, Suresnes

2023-02-28

Active, closed

A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.

NCT05637112Systemic Lupus Erythematosus

AstraZeneca

Observational

551

Nice, Clermont-Ferrand, Strasbourg, Finist Re, Dijon, Bordeaux, Grenoble, Saint-Denis

2023-02-27

Recruiting

Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer

NCT05346848Prostate Cancer

Institut Bergonié

Phase 2

Avignon, Besançon, Bordeaux, Brest, Marseille, Paris, Saint-Grégoire, Saint-Herblain

2023-02-24

Active, closed

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

NCT05676931Advanced Non-Small Cell Lung Cancer

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Docetaxel

Gilead Sciences

Phase 2

400

Bordeaux, Lyon, Strasboug, Suresnes

2023-02-21

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors

Fore Biotherapeutics

Phase 2

254

Bordeaux, Marseille, Brest, Angers, Villejuif, Toulouse, Paris

2023-02-21

Recruiting

Medico-economic Evaluation Rehabilitation by Serious Games at Home for the Management of Patients With Parkinson's Disease Suffering From Gait and Balance Disorders

NCT04720365Patients With Parkinson's Disease

University Hospital, Rouen

Not applicable

Bordeaux, Lille, Paris, Rouen

2023-02-15

Active, closed

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034Ischemic Stroke; Ischemic Attack, Transient

DrugMilvexian

Janssen Research & Development, LLC

Phase 3

12,523

Aix-en-Provence, Besançon, Bordeaux, Bourg-en-Bresse, Brest, Bron, Chartres, Clermont-Ferrand

2023-02-15

Active, closed

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899High-risk Large B-cell Lymphoma (LBCL)

DrugsAxi-cel·Axicabtagene Ciloleucel·Vincristine·Doxorubicin

Kite, A Gilead Company

Phase 3

300

Bordeaux, Cedex Lyon 08, Dijon, Lille, Montpellier, Nice, Paris, Rennes

2023-02-10

Recruiting

Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

NCT05496998Mitral Regurgitation

Medtronic Cardiovascular

Not applicable

400

Toulouse, Bordeaux, Créteil, Marseille, Nantes, Rennes, Saint-Denis, Tours

2023-02-07

Recruiting

Chronic Airway Disease, Mucus Rheology and Exacerbations

NCT04339270Chronic Obstructive Pulmonary Disease

University Hospital, Montpellier

Phase 4

Bordeaux, Montpellier, Toulouse

2023-02-03

Active, closed

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT05686551Huntington Disease

Hoffmann-La Roche

Phase 2

301

Angers, Bordeaux, Créteil, Lille, Marseille, Montpellier, Strasbourg, Toulouse

2023-02-03

Active, closed

Evaluation of the Efficacy of HIFU Treatment on Rectal Endometriosis Symptoms.

NCT05755958Endometriosis

EDAP TMS S.A.

Not applicable

Aix-en-Provence, Angers, Bordeaux, Clermont-Ferrand, Le Kremlin-Bicêtre, Lille, Lyon, Paris

2023-02-03

Recruiting

Non-Invasive Ventilation Versus High-flow Nasal Oxygen in Intensive Care Units

NCT05686850Post Extubation Respiratory Failure

Poitiers University Hospital

Not applicable

670

Angers, Argenteuil, Aurillac, Avignon, Belfort, Bordeaux, Bourg-en-Bresse, Brest

2023-02-02

Recruiting

Evaluation of A Clinical Diagnostic Test for CRDS

NCT06188689Calcium Release Deficiency Syndrome (CRDS)

Population Health Research Institute

Not applicable

400

Bordeaux

2023-02-02

Recruiting

Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis

NCT04789850Systemic Sclerosis

DrugItacitinib

Assistance Publique - Hôpitaux de Paris

Phase 2

Amiens, Angers, Annecy, Besançon, Bobigny, Bordeaux, Boulogne-Billancourt, Brest

2023-02-02

Active, closed

Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer.

NCT05690828Breast Cancer

Institut Bergonié

Not applicable

164

Bordeaux

2023-02-01

Recruiting

Women Hypertensive and Young-Renal Denervation

NCT05563337Arterial Hypertension

University Hospital, Bordeaux

Not applicable

Bordeaux, Grenoble, Lille, Nantes, Paris, Toulouse

2023-01-31

Active, closed

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors

NCT05219318Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score

DrugVegfr-Tki

University Hospital, Bordeaux

Phase 3

Bayonne, Bordeaux, Caen, Clermont-Ferrand, Créteil, Dijon, Grenoble, Limoges

2023-01-23

Active, closed

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

NCT05405361Multifocal Motor Neuropathy (MMN)

DrugEmpasiprubart

argenx

Phase 2

Bordeaux, Lille, Nice, Paris

2023-01-18

Active, closed

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,564

Dijon, Besançon, Bordeaux, Toulouse, Lille, Montpellier, La Tronche, Caen

2023-01-16

Recruiting

Optimisation Strategy for Emergency Tracheal Intubation

NCT05539391Emergencies, Out-of-hospital Setting, Tracheal Intubation

University Hospital, Bordeaux

Not applicable

1,500

Angers, Beaumont-sur-Oise, Bobigny, Bordeaux, Cergy-Pontoise, Créteil, Dijon, Eaubonne

2023-01-14

Recruiting

Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.

NCT05102747Brain Metastasis, Oligoprogression

Centre Francois Baclesse

Not applicable

504

Bordeaux, Brest, Caen, Grenoble, Le Havre, Lorient, Nice, Paris

2023-01-12

Recruiting

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

DrugsVepugratinib·Digoxin·Enfortumab Vedotin·Rosuvastatin

Eli Lilly and Company

Phase 1

677

Bordeaux, Lyon, Villejuif

2023-01-12

Active, closed

French Registry Conducted on E-vita OPEN NEO

NCT05721001Vascular Aneurysm

JOTEC GmbH

Observational

130

Amiens, Angers, Annecy, Besançon, Bordeaux, Brest, Bron, Caen

2023-01-11

Active, closed

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Pemetrexed·Keytruda·Cisplatin

Daiichi Sankyo

Phase 3

1,170

Avignon, Besançon, Bordeaux, France, Lyon, Marseille, Montpellier, Nantes

2023-01-11

Recruiting

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

NCT05658575Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis

DrugDapansutrile

Olatec Therapeutics, Inc.

Phase 2/3

300

Bordeaux, Lomme, Paris, Rouen

2023-01-06

Active, closed

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

NCT05024773Bladder Carcinoma in Situ (CIS)

Fidia Farmaceutici s.p.a.

Phase 3

130

Bordeaux, Clermont-Ferrand, Lille, Marseille, Paris, Poitiers

2022-12-29

Recruiting

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

NCT05752552Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer

DeuterOncology

Phase 1

Bordeaux, Lille, Lyon, Marseille, Nice, Rennes, Villejuif

2022-12-20

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297Advanced Melanoma

DrugTebentafusp

Immunocore Ltd

Phase 3

540

Lyon, Toulouse, Villejuif, Bordeaux, Marseille, Paris

2022-12-19

Recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

NCT05327894Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia

DrugBlinatumomab

Princess Maxima Center for Pediatric Oncology

Phase 3

160

Amiens, Besançon, Bordeaux, Grenoble, Lille, Lyon, Marseille, Montpellier

2022-12-15

Recruiting

Low Impact Laparoscopic in Colorectal Resection - PAROS2

NCT04742881Malignant or Benign Pathology

University Hospital, Bordeaux

Not applicable

148

Bayonne, Bordeaux, Libourne

2022-12-14

Active, closed

Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls

NCT05575830RZV Vaccine (Shingrix ®)

DrugRecombinant Zoster Vaccine

Calmy Alexandra

Phase 4

225

Bordeaux, Pessac

2022-12-14

Recruiting

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

NCT05650229Primary Mitochondrial Disease

DrugNapazimone

Pharming Technologies B.V.

Phase 2

180

Angers, Bordeaux, Lille, Nantes, Nice, Paris, Strasbourg

2022-12-13

Active, closed

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

696

Angers, Antony, Bordeaux, Brest, Montpellier, Nice, Paris, Pierre-Bénite

2022-12-09

Active, closed

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

NCT05501886Breast Cancer

DrugsGedatolisib·Alpelisib·Palbociclib·Fulvestrant

Celcuity Inc

Phase 3

701

Bordeaux, Caen, La Roche-sur-Yon, Marseille, Poitiers, Strasbourg, Villejuif

2022-12-08

Recruiting

Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma

NCT05429138Melanoma

Assistance Publique Hopitaux De Marseille

Observational

Bordeaux, Marseille, Montpellier, Nantes, Nice, Nîmes, Paris, Toulouse

2022-12-07

Active, closed

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

NCT04968106Resectable Sarcoma

DrugsRetifanlimab·Ifosfamide·Doxorubicin

Institut Bergonié

Phase 2

Bordeaux, Lyon, Paris

2022-12-07

Recruiting

Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention

NCT05433441Parkinson Disease

University Hospital, Bordeaux

Not applicable

250

Bordeaux, Lille, Limoges, Poitiers

2022-12-06

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

NCT05599984Advanced Solid Tumors

DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin

AbbVie

Phase 1

288

Bordeaux, Villejuif, Montpellier

2022-12-05

Active, closed

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

NCT05688280Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma

DrugIP-001

Immunophotonics, Inc.

Phase 1/2

Bordeaux, Paris, Suresnes, Villejuif

2022-11-29

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Angers, Bordeaux, Dijon, Lyon, Montpellier, Nîmes, Paris, Poitiers

2022-11-28

Recruiting

Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis

NCT05428488Rheumatoid Arthritis

DrugAbatacept

University Hospital, Montpellier

Phase 3

220

Montpellier, Bordeaux, Brest, Cahors, La Roche-sur-Yon, Le Mans, Nantes, Nice

2022-11-28

Recruiting

Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis

NCT05428826Idiopathic Retroperitoneal Fibrosis

DrugPrednisone

Assistance Publique - Hôpitaux de Paris

Phase 4

Agen, Brest, Bordeaux, Boulogne-Billancourt, Créteil, Dijon, Lille, Marseille

2022-11-25

Active, closed

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

DrugsAsciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

568

Bordeaux, Caen, Clermont-Ferrand, Lille, Lyon, Marseille, Nantes, Nice

2022-11-21

Recruiting

Evaluation of the Efficacy of Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults

NCT05157685Sinusitis, Chronic, Sinus Infection Chronic

DrugAzithromycin

Centre Hospitalier Intercommunal Creteil

Phase 3

230

Bordeaux, Créteil, Le Kremlin-Bicêtre, Lille, Lyon, Marseille, Nancy, Nantes

2022-11-21

Active, closed

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Observational

6,000

Strasbourg, Marseille, Dijon, Bordeaux, Nantes, Saint-Étienne-de-Montluc, Lyon, Rouen

2022-11-21

Recruiting

Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial Protocol

NCT05320263Basilar Artery Occlusion

Hopital Foch

Not applicable

480

Bordeaux, Caen, Limoges, Montpellier, Nancy, Nantes, Paris, Reims

2022-11-19

Recruiting

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

NCT05533775Mature B-Cell Non-Hodgkin Lymphoma

DrugsIfosfamide·Glofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 1/2

Bordeaux, Villejuif

2022-11-16

Active, closed

A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.

NCT05683977Small Cell Lung Carcinoma

DrugDurvalumab

AstraZeneca

Observational

254

Angers, Argenteuil, Avignon, Bayonne, Bordeaux, Clermont-Ferrand, Créteil, Dijon

2022-11-14

Recruiting

Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease

NCT05306834Cerebral Small Vessel Diseases, Stroke, Dementia

University Hospital, Bordeaux

Not applicable

400

Bordeaux, Paris

2022-11-10

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

Bordeaux, Toulouse, Bron, Montpellier, Strasbourg, Paris

2022-11-08

Active, closed

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

822

Bordeaux, Bron, Créteil, Lille, Montpellier, Nice, Paris, Pierre-Bénite

2022-11-08

Recruiting

PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)

NCT04790253Limited Stage Small Cell Lung Cancer, Extensive-stage Small-cell Lung Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Not applicable

600

Angers, Avignon, Bayonne, Bordeaux, Caen, Chambéry, Cholet, Créteil

2022-10-27

Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms

DrugsPF-08046054·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

714

Bordeaux, Neuilly-sur-Seine, Paris, Villejuif

2022-10-25

Active, closed

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378Lung Cancer, Non-Small Cell

DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 2

351

Bordeaux, Caen, Marseille, Quimper, Strasbourg

2022-10-14

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Lyon, Strasbourg, Bordeaux, Caen, Montpellier, Angers, Saint-Herblain, Paris

2022-10-14

Active, closed

Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine

NCT05201352Metastatic Colorectal Cancer

DrugTrifluridine/Tipiracil

Centre Georges Francois Leclerc

Phase 1/2

160

Dijon, Angers, Avignon, Besançon, Bordeaux, Carcassonne, Clermont-Ferrand, Levallois-Perret

2022-10-13

Active, closed

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

NCT05537740Advanced Solid Tumors

DrugPembrolizumab

Bayer

Phase 1

129

Lille, Bordeaux, Saint-Herblain, Villejuif

2022-10-11

Recruiting

Electroclinical Correlation of Anxiety

NCT05393518Anxiety Disorder, Generalized Anxiety Disorder, Drug Resistant Epilepsy

University Hospital, Bordeaux

Not applicable

Bordeaux

2022-10-11

Active, closed

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

NCT05206357Non-hodgkin Lymphoma

DrugEpcoritamab

Genmab

Phase 1

Bordeaux, Nantes, Villejuif, Lyon

2022-10-04

Active, closed

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054Breast Neoplasms

DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole

Eli Lilly and Company

Phase 3

8,000

Avignon, Bayonne, Besançon, Bordeaux, Brest, Clermont-Ferrand, Créteil, La Chaussée-Saint-Victor

2022-10-04

Recruiting

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

NCT05443126NSCLC

DrugPemetrexed

Ellipses Pharma

Phase 1/2

265

Bordeaux, Caen, Lyon, Marseille, Paris

2022-09-30

Recruiting

Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction

NCT05574244Benign Prostatic Hyperplasia

University Hospital, Bordeaux

Not applicable

336

Aix-en-Provence, Angers, Bordeaux, Créteil, Lille, Limoges, Marseille, Nice

2022-09-29

Recruiting

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

NCT05476939Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered

DrugsDordaviprone·Everolimus

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

433

Villejuif, Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand

2022-09-29

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

201

Bordeaux, Bron, Le Kremlin-Bicêtre, Marseille, Nice, Nîmes, Paris, Strasbourg

2022-09-23

Active, closed

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

NCT05440786Sarcoma, Ewing, Neoplasm Metastasis

DrugsAbemaciclib·Temozolomide·Irinotecan

Eli Lilly and Company

Phase 2

Bordeaux, Lyon

2022-09-20

Active, closed

Determinants of Daily Physical Activity Level in Patients With Cystic Fibrosis - Pilot Study Protocol

NCT05206097Cystic Fibrosis

University Hospital, Limoges

Not applicable

Bordeaux, Limoges, Toulouse

2022-09-19

Active, closed

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor

DrugElironrasib

Revolution Medicines, Inc.

Phase 1

222

Angers, Bordeaux, Clermont-Ferrand, Lille, Lyon, Nantes, Strasbourg

2022-09-19

Recruiting

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

NCT05384821Wilms Tumor

DrugsTemozolomide·Vincristine·Irinotecan·Etoposide

Centre Oscar Lambret

Phase 1/2

Amiens, Besançon, Bordeaux, Grenoble, Lille, Lyon, Marseille, Montpellier

2022-09-14

Recruiting

MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2

NCT05691608Solid Tumor, Leukemia

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

1,800

Amiens, Paris, Saint-Etienne, Angers, Besançon, Bordeaux, Brest, Caen

2022-09-09

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

NCT05243797Multiple Myeloma

DrugsTeclistamab·Lenalidomide

European Myeloma Network B.V.

Phase 3

1,594

Bordeaux, Lille, Marseille, Montpellier, Nantes, Paris, Poitiers, Toulouse

2022-09-08

Active, closed

Genetics of Ventriculo-arterial Discordance

NCT05330338Heart Defects, Congenital

Nantes University Hospital

Not applicable

600

Marseille, Rennes, Bordeaux, Toulouse, Lille, Le Plessis-Robinson, Nantes, Saint-Herblain

2022-09-07

Recruiting

De-escalation Study for Stage IIa/IIb < 3 cm Seminoma

NCT05529251Seminoma, Stage II

DrugCarboplatin AUC7

Centre Leon Berard

Phase 2

Besançon, Bordeaux, Caen, Clermont-Ferrand, Lille, Limoges, Lyon, Marseille

2022-09-06

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Bordeaux, Lyon, Marseille, Suresnes

2022-09-06

Active, closed

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

NCT04074096Malignant Melanoma, BRAF V600 Mutation, Brain Metastases

DrugsBinimetinib·Encorafenib·Keytruda·Pembrolizumab

UNICANCER

Phase 2

Bobigny, Bordeaux, Boulogne-Billancourt, Caen, Créteil, Dijon, Lyon, Marseille

2022-09-05

Recruiting

Asciminib Roll-over Study

NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 4

347

Bordeaux, Lyon, Marseille, Nantes, Paris, Vandœuvre-lès-Nancy

2022-08-30

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Antony, Bordeaux, Clermont-Ferrand, Créteil, Lille, Nice, Reims, Rouen

2022-08-22

Active, closed

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

NCT05327530Locally Advanced or Metastatic Urothelial Carcinoma

DrugsAvelumab·Sacituzumab Govitecan

EMD Serono Research & Development Institute, Inc.

Phase 2

256

Suresnes, Angers, Bordeaux, Caen, Créteil, Le Mans, Lyon, Marseille

2022-08-17

Recruiting

International Study of Cerebral Oxygenation and Electrical Activity During Major Neonatal Surgery

NCT05673499Congenital Disorders, Cerebral Desaturation, Neonatal Surgery

Children's Hospital of Philadelphia

Observational

900

Bordeaux

2022-08-12

Active, closed

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS

DrugsNorditropin·Somapacitan

Novo Nordisk A/S

Phase 3

412

Angers, Bordeaux, Le Kremlin-Bicêtre, Marseille, Marseille Cédex 05, Paris, Toulouse

2022-08-10

Recruiting

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

NCT05410145KRAS P.G12C

DrugsD3S-001·Cetuximab·Pemetrexed·Cisplatin

D3 Bio (Wuxi) Co., Ltd

Phase 1/2

442

Bordeaux, Lyon, Rennes, Villejuif

2022-08-03

Active, closed

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases

DrugIDRX-42

IDRX, Inc., a wholly owned subsidiary of GSK, LLC

Phase 1

276

Bordeaux, Lyon, Marseille, Villejuif

2022-08-03

Recruiting

Transplantation After Complete Response In Patients With T-cell Lymphoma

NCT05444712Peripheral T Cell Lymphoma

Hospices Civils de Lyon

Not applicable

204

Amiens, Angers, Argenteuil, Avignon, Bayonne, Bordeaux, Chambéry, Clermont-Ferrand

2022-08-01

Active, closed

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Triple Negative Breast Cancer, PD-L1 Positive

DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel

Gilead Sciences

Phase 3

443

Avignon, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Lyon, Marseille

2022-07-25

Active, closed

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Phesgo·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

922

Avignon, Bayonne, Besançon, Bordeaux, Grenoble, La Roche-sur-Yon, Lyon, Paris

2022-07-18

Active, closed

The TRICURE First in Human Trial

NCT05126030Tricuspid Regurgitation

TRiCares

Not applicable

Bordeaux, Bron, Créteil, Lille, Marseille, Rennes, Saint-Denis

2022-07-15

Active, closed

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277Lupus Nephritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

452

Besançon, Bordeaux, Grenoble, Lyon, Marseille, Poitiers, Toulouse, Vandœuvre-lès-Nancy

2022-07-14

Active, closed

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

NCT05352672Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,546

Pierre-Bénite, Dijon, Besançon, Bordeaux, Lille, La Tronche, Poitiers, Rouen

2022-07-14

Recruiting

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

NCT05198960Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F

DrugAspirin

University Hospital, Brest

Phase 3

1,308

Angers, Annecy, Argenteuil, Avignon, Bayonne, Béziers, Bordeaux, Brest

2022-07-13

Active, closed

Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)

NCT05164055Glycogen Storage Disease Type II

DrugAvalglucosidase alfa

Genzyme, a Sanofi Company

Phase 4

Bordeaux, Brest, Clermont-Ferrand, Lille, Lyon, Marseille, Nantes, Nice

2022-07-11

Active, closed

Study of INCB123667 in Subjects With Advanced Solid Tumors

NCT05238922Solid Tumors

DrugsRibociclib·Palbociclib·Olaparib·Fulvestrant

Incyte Corporation

Phase 1

291

Bordeaux, Lyon, Toulouse, Villejuif

2022-07-05

Not yet open

Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma

NCT05298293Diffuse Large B Cell Lymphoma

Weprom

Not applicable

160

Bordeaux, Le Mans, Nantes, Saint-Nazaire, Strasbourg

2022-07-01

Recruiting

Implementing Precision Medicine in cOmmunity HospiTALs

NCT05283044Metastatic Cancer

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

10,000

Bayonne, Bligny, Bordeaux, Corbeil-Essonnes, Épagny, Grenoble, La Réunion, Melun

2022-06-29

Recruiting

Validation of the French Version of the CQR (Compliance Questionnaire Rheumatology)

NCT03642795Rheumatoid Polyarthritis

Centre Hospitalier Universitaire de Nīmes

Observational

150

Bordeaux, Montpellier, Nîmes, Toulouse

2022-06-23

Recruiting

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

NCT05378204Breast Cancer

Institut Claudius Regaud

Not applicable

120

Bordeaux, Caen, Clermont-Ferrand, Dijon, La Roche-sur-Yon, Lille, Limoges, Lyon

2022-06-23

Recruiting

Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk

NCT05098704Scleroderma, Systemic Sclerosis

University Hospital, Bordeaux

Phase 2/3

Bayonne, Bordeaux, Brest, Grenoble, Libourne, Mont-de-Marsan, Paris, Pau

2022-06-22

Active, closed

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

NCT05382156Endogenous Cushing's Syndrome

DrugOsilodrostat

RECORDATI GROUP

Observational

206

Bordeaux, Bron, Grenoble, Le Kremlin-Bicêtre, Lille, Marseille, Nancy, Nantes

2022-06-13

Recruiting

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

NCT04672733Chronic Inflammatory Demyelinating Polyneuropathy

DrugHizentra

CSL Behring

Observational

100

Amiens, Angers, Aubagne, Bayonne, Bordeaux, Brest, Créteil, Le Kremlin-Bicêtre

2022-06-10

Active, closed

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

NCT05329766Gastrointestinal Tract Malignancies

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Fluorouracil

Arcus Biosciences, Inc.

Phase 2

332

Bordeaux, Brest, Caen, Lille, Lyon, Marseille, Montpellier, Plérin

2022-06-10

Active, closed

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

NCT05156710Transplant Rejection

DrugsAntithymocyte globulin·Riliprubart·Immunoglobulin·IVIG

Sanofi

Phase 2

Bordeaux, Créteil, Paris, Toulouse

2022-06-09

Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559Solid Tumor

DrugsNanoparticle albumin-bound-paclitaxel·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Inc

Phase 1

681

La Tronche, Bordeaux, Lyon, Villejuif

2022-06-08

Active, closed

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

NCT05175105Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

Bordeaux

2022-06-06

Recruiting

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

NCT05183646FSGS

DrugRepagermanium

Dimerix Bioscience Pty Ltd

Phase 3

286

Bordeaux, Créteil, Grenoble, La Roche-sur-Yon, Marseille, Montpellier, Paris, Saint-Priest-en-Jarez

2022-05-30

Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

NCT05434234Advanced Solid Tumor

DrugTam-Peli

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

312

Bordeaux, Dijon, Marseille, Nantes, Paris, Poitiers, Saint-Herblain, Suresnes

2022-05-25

Active, closed

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370Neurofibromatosis Type 1

AstraZeneca

Observational

124

Amiens, Angers, Bordeaux, Lille, Lyon, Marseille, Paris, Rennes

2022-05-23

Recruiting

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml

DrugELVN-001

Enliven Therapeutics

Phase 1

250

Amiens, Bordeaux, Lille, Limoges, Lyon, Pierre-Bénite

2022-05-22

Active, closed

Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults

NCT05210413Refractory or Recurrent Solid Tumor

University Hospital, Bordeaux

Phase 1/2

Angers, Bordeaux, Lille, Lyon, Marseille, Nantes, Paris, Strasbourg

2022-05-17

Active, closed

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

NCT05155254Metastatic Melanoma, Unresectable Melanoma

DrugsIO102-IO103·Pembrolizumab

IO Biotech

Phase 3

407

Besançon, Bordeaux, Boulogne-Billancourt, Dijon, La Tronche, Lille, Marseille, Nice

2022-05-17

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Bordeaux, Dijon, Limoges, Lyon, Marseille, Montpellier, Paris, Rouen

2022-05-16

Active, closed

Observational Study of the Use of 8% Capsaicin Patch in Children 0 to 18 Years Old

NCT05299294Neuropathic Pain, Chronic Pain

University Hospital, Brest

Observational

160

Angers, Bordeaux, Bourg-en-Bresse, Brest, Caen, Lille, Limoges, Marseille

2022-05-12

Recruiting

VIP - Vascular Infection Project

NCT06866535Aortitis, Vascular Graft Infection, Blood Vessel Prosthesis, Infections

University Hospital, Bordeaux

Observational

1,000

Bordeaux

2022-05-10

Recruiting

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

NCT05310643Metastatic Colorectal Cancer

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2

Besançon, Bordeaux, Lille, Limoges, Lyon, Montpellier, Nice, Paris

2022-05-05

Recruiting

Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy

NCT05180825Grade 1 Glioma, Mixed Glio-neuronal Tumors, Pleomorphic Xanthoastrocytoma

DrugsVinblastine·Trametinib

University Hospital, Strasbourg, France

Phase 2

134

Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Dijon, Grenoble

2022-05-05

Active, closed

Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin

NCT05514028Ovarian Cancer, Ovarian Cyst Benign, Borderline Ovarian Cancer

ZIWIG

Observational

746

Caen, Dijon, Bordeaux, Strasbourg, Toulouse, Saint-Grégoire, Le Kremlin-Bicêtre, Villejuif

2022-05-04

Active, closed

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

1,300

Caen, Nancy, Bordeaux, Bron, Clermont-Ferrand, Lille, Nice, Poissy

2022-05-03

Active, closed

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044Melanoma

Pierre Fabre Medicament

Phase 3

815

Nice, Marseille, Dijon, Bordeaux, Toulouse, Boulogne-Billancourt, Rennes, Chambray-lès-Tours

2022-05-02

Recruiting

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

NCT05255302Metastatic NSCLC

DrugPemetrexed

Intergroupe Francophone de Cancerologie Thoracique

Phase 2/3

1,360

Aix-en-Provence, Amiens, Angers, Avignon, Besançon, Bordeaux, Caen, Cannes

2022-05-02

Recruiting

Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

NCT05182164Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma, Ewing Sarcoma, Osteosarcoma

DrugCabozantinib

Institut Bergonié

Phase 2

119

Bordeaux, Dijon, Lille, Lyon, Marseille, Paris, Saint-Herblain, Toulouse

2022-04-25

By invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

NCT05303532Cancer

DrugDurvalumab

AstraZeneca

Phase 3

214

Besançon, Bordeaux, Brest, Dijon, Lyon, Marseille, Montpellier, Rennes

2022-04-19

Recruiting

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

NCT04916613Prostate Cancer Metastatic

DrugDarolutamide

UNICANCER

Phase 3

300

Avignon, Bayonne, Besançon, Beuvry, Bordeaux, Brest, Caen, Chambéry

2022-04-19

Active, closed

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

NCT05180695Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma

DrugsSiremadlin·Pazopanib

Centre Leon Berard

Phase 1/2

Bordeaux, Lyon, Marseille, Toulouse, Villejuif

2022-04-15

Active, closed

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

NCT05201547Endometrial Cancer

DrugsCarboplatin/Paclitaxel·Dostarlimab

ARCAGY/ GINECO GROUP

Phase 3

260

Amiens, Angers, Auxerre, Avignon, Beauvais, Besançon, Bordeaux, Brest

2022-04-15

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550Non-small Cell Lung Cancer

DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab

AstraZeneca

Phase 2

630

Avignon, Bobigny, Bordeaux, Limoges, Rennes, Rouen, Suresnes, Toulon

2022-04-14

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer

DrugsBezuclastinib·Sunitinib·Midazolam

Cogent Biosciences, Inc.

Phase 3

482

Bordeaux, Lille, Lyon, Marseille, Rennes, Saint-Herblain, Toulouse, Villejuif

2022-04-14

Recruiting

Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis

NCT04227314Recurrent Aphtous Stomatitis

DrugApremilast

University Hospital, Rouen

Phase 3

134

Amiens, Bobigny, Bordeaux, Brest, Créteil, Le Mans, Lille, Lyon

2022-04-10

Recruiting

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

NCT04985266ER+ Breast Cancer, HER2-negative Breast Cancer

DrugsTamoxifen·Exemestane·Anastrozole·Letrozole

Royal Marsden NHS Foundation Trust

Phase 2

1,100

Angers, Annecy, Avignon, Blois, Bordeaux, Clermont-Ferrand, Dijon, Grenoble

2022-03-30

Active, closed

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease

DrugTulisokibart

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

154

Bordeaux, Lille, Paris

2022-03-29

Active, closed

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035Chronic Kidney Disease, Proteinuria

DrugFinerenone

Bayer

Phase 3

219

Bron, Strasbourg, Bordeaux, Montpellier, Toulouse, Paris

2022-03-28

Active, closed

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577Prostate Cancer

DrugsCapivasertib·Docetaxel

AstraZeneca

Phase 3

1,035

Bordeaux, Brest, Clermont-Ferrand, Créteil, Montpellier, Paris, Rouen, Saint-Herblain

2022-03-25

Recruiting

Clinical Assessment of Essential Remote Monitoring Functions in Pacemakers

NCT05165095Bradycardia, Remote Monitoring

MicroPort CRM

Observational

206

Bordeaux, Le Coudray, Marseille, Nantes, Toulouse, Valence

2022-03-25

Recruiting

Biobank and Brain Health in Bordeaux.

NCT05322343Brain, Aging, Cognitive Aging, Immunosenescence

University Hospital, Bordeaux

Observational

2,050

Bordeaux

2022-03-22

Recruiting

STUDY OF THE ADDED VALUE OF A TRANSMURAL EVALUATION IN PATIENTS WITH CROHN'S DISEASE UNDER BIOTHERAPY WITH CLOSE FECAL CALPROTECTIN FOLLOW-UP

NCT04973423Crohn Disease, Calprotectin, MRI

University Hospital, Clermont-Ferrand

Not applicable

180

Amiens, Aurillac, Bayonne, Bordeaux, Chambéry, Clermont-Ferrand, Grenoble, Issoire

2022-03-21

Active, closed

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

530

Bordeaux, Grenoble, Clermont-Ferrand, Reims, Nîmes, Mulhouse, Amiens, Nantes

2022-03-15

Active, closed

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567Breast Neoplasm, Neoplasm Metastasis

DrugsAbemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

368

Bordeaux, Brest, Nantes, La Roche-sur-Yon

2022-03-11

Active, closed

LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB

NCT05210621Multiple Sclerosis

DrugOcrelizumab

Centre Hospitalier Universitaire de Nice

Phase 3

Amiens, Bayonne, Bordeaux, Caen, Clermont-Ferrand, Lille, Lyon, Marseille

2022-03-08

Active, closed

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

NCT05078047Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer

UNICANCER

Phase 3

646

Angers, Avignon, Bayonne, Bordeaux, Boulogne-sur-Mer, Caen, Clermont-Ferrand, Créteil

2022-03-08

Active, closed

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582HER2 Positive Breast Cancer

DrugsPerjeta·Tucatinib·Herceptin·Pertuzumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

654

Rouen, Bordeaux, Montpellier, Saint-Herblain, Avignon, Dijon, Besançon, Bobigny

2022-03-07

Active, closed

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

NCT05215340Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

740

Avignon, Bordeaux, Lille, Lyon, Marseille, Montpellier, Nantes, Paris

2022-03-04

Recruiting

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

NCT04775706Short Bowel Syndrome

Hanmi Pharmaceutical Company Limited

Phase 2

Clichy, Bordeaux, Lyon, Nice

2022-03-03

Active, closed

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

NCT04874311Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma

DrugsBintrafusp alfa·Doxorubicin

Institut Bergonié

Phase 2

Bordeaux, Dijon, Lyon, Marseille, Paris, Poitiers

2022-03-01

Active, closed

Chronic Pain and Hemophilia

NCT05202951Chronic Pain, Hemophilia

University Hospital, Clermont-Ferrand

Observational

350

Bordeaux, Caen, Chambéry, Clermont-Ferrand, Grenoble, Lille, Lyon, Nantes

2022-02-28

Active, closed

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

NCT05138133Lupus Nephritis

DrugAnifrolumab

AstraZeneca

Phase 3

363

Aurillac, Bordeaux, Marseille, Paris, Strasbourg, Toulouse

2022-02-15

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

NCT05031780Sickle Cell Disease

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 2/3

286

Marseille, Bordeaux, Pointe à Pitre, Toulouse, Créteil, Paris

2022-02-11

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Avignon, Besançon, Bordeaux, Clermont-Ferrand, Créteil, Lorient, Marseille, Montpellier

2022-02-07

Recruiting

Better Understand Motor Deficits Associated With Autism Spectrum Disorders: Development of an Assessment Protocol

NCT05236803Autism Spectrum Disorder

Centre Hospitalier Charles Perrens, Bordeaux

Not applicable

110

Bordeaux, La Rochelle, Limoges, Poitiers

2022-02-07

Recruiting

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

NCT05183984Ovarian Cancer

DrugsBevacizumab-awwb·Niraparib

ARCAGY/ GINECO GROUP

Phase 2

390

Angers, Avignon, Besançon, Bordeaux, Brest, Bron, Caen, Cholet

2022-02-01

Recruiting

Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers

NCT05267912Advanced, Pretreated Solid Tumors

Gustave Roussy, Cancer Campus, Grand Paris

Not applicable

152

Bordeaux, Lille, Lyon, Paris, Poitiers, Reims, Rennes, Saint-Mandé

2022-01-19

Active, closed

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

DrugsEvorpacept·Ramucirumab·Herceptin·Taxol

ALX Oncology Inc.

Phase 2/3

127

Besançon, Bordeaux, Brest, Lyon, Marseille, Paris, Toulouse

2022-01-15

Active, closed

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

NCT05152472Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor

DrugsGlivec·Imatinib·Tecentriq·Atezolizumab

Centre Leon Berard

Phase 2

Lyon, Bordeaux, Lille, Marseille, Nice, Poitiers, Reims, Rennes

2022-01-14

Recruiting

The "Global Paradise System" Registry

NCT05027685Hypertension

ReCor Medical, Inc.

Observational

3,000

Grenoble, Bordeaux, Marseille, Paris, Pau

2022-01-13

Recruiting

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression

NCT05126849Refractory Idiopathic Aplastic Anemia, Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Assistance Publique - Hôpitaux de Paris

Phase 2

Amiens, Angers, Besançon, Bordeaux, Caen, Clamart, Clermont-Ferrand, Créteil

2022-01-06

Recruiting

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

NCT05009927Metastatic Gastrointestinal Stromal Tumor (GIST), C-KIT Mutation, Advanced Gastrointestinal Stromal Tumor (GIST)

DrugsGlivec·Imatinib

Centre Leon Berard

Phase 2

Besançon, Bordeaux, Limoges, Lyon, Marseille, Paris, Reims, Rennes

2022-01-03

Recruiting

Cocreation and Evaluation of an Escape Game on Students' Mental Health

NCT06720792Mental Health

University of Bordeaux

Not applicable

191

Bordeaux

2022-01-01

Recruiting

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

NCT04925479Myeloid Leukemia, Philadelphia Positive

DrugABL001

Novartis Pharmaceuticals

Phase 1/2

Bordeaux, Lille, Paris, Poitiers

2021-12-27

Active, closed

Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

NCT04974216DLBCL

DrugsTafasitamab·Lenalidomide·Rituximab

The Lymphoma Academic Research Organisation

Phase 2

Avignon, Bayonne, Besançon, Bordeaux, Corbeil-Essonnes, La Roche-sur-Yon, Lille, Limoges

2021-12-20

Active, closed

Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

NCT05041842Metastatic Breast Cancer With a Isolated Brain Progression

DrugsPertuzumab/Trastuzumab·Phesgo·Perjeta·Tucatinib

UNICANCER

Phase 2

Angers, Bordeaux, Caen, Dijon, Le Mans, Lyon, Montpellier, Nice

2021-12-17

Active, closed

French eCLIPs™ Efficacy and Safety Investigation

NCT05330897Intracranial Aneurysm

Evasc Medical Systems Corp.

Not applicable

119

Amiens, Bordeaux, Brest, Bron, Caen, Clermont-Ferrand, Colmar, Cornebarrieu

2021-12-16

Active, closed

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

NCT04998786Multiple Myeloma at First Relapse

DrugsIxazomib·Iberdomide·Dexamethasone

Nantes University Hospital

Phase 2

Annecy, Bayonne, Bordeaux, Caen, Clermont-Ferrand, Dijon, La Roche-sur-Yon, Lille

2021-12-14

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab

Exelixis

Phase 1

1,394

Besançon, Bordeaux, Caen, Clermont-Ferrand, Lyon, Marseille, Nice, Paris

2021-12-14

Active, closed

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

NCT04982393Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals

Observational

207

Bordeaux, Lyon, Paris

2021-12-13

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer

DrugsRLY-2608·Atirmociclib·Ribociclib·Palbociclib

Relay Therapeutics, Inc.

Phase 1

930

Lyon, Bordeaux, Villejuif

2021-12-08

Recruiting

A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery

NCT04702581Oligodendroglioma, Low-grade Oligodendroglioma, 1p19q Codeletion

Hospices Civils de Lyon

Phase 3

280

Amiens, Angers, Bordeaux, Brest, Bron, Caen, Clamart, Colmar

2021-12-07

Active, closed

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)

NCT05215106Early Small (cT1N0) Triple Negative Breast Cancer

DrugDurvalumab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2

200

Bordeaux, Lyon, Villejuif

2021-12-06

Active, closed

Observatory of Patients With Haemophilia B Treated by IdElvion®

NCT05086575Haemophilia B

CSL Behring

Observational

222

Amiens, Annecy, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Dijon

2021-12-03

Active, closed

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil

Jazz Pharmaceuticals

Phase 3

920

Pessac, Avignon, Bordeaux, Dijon, Grenoble, Lyon, Nantes, Poitiers

2021-12-02

Recruiting

Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

NCT04747054Squamous Cell Carcinoma of Head and Neck

DrugsKeytruda·Pembrolizumab

UNICANCER

Phase 3

102

Avignon, Besançon, Bordeaux, Caen, Carcassonne, Clermont-Ferrand, Dijon, Le Havre

2021-12-01

Recruiting

Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma

NCT04749108Locally Advanced Malignant Neoplasm, Rectal Carcinoma

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2/3

1,075

Marseille, Besançon, Bordeaux, Montpellier, Vandœuvre-lès-Nancy, Nancy, Lille, Amiens

2021-11-26

Active, closed

VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.

NCT03686306Peripheral Artery Disease

DrugSildenafil

Rennes University Hospital

Phase 3

106

Rennes, Amiens, Bordeaux, Caen, Cholet, Grenoble, Mulhouse, Nîmes

2021-11-24

Recruiting

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

NCT05255653Endometrial Cancer

DrugDurvalumab

Leiden University Medical Center

Phase 3

316

Besançon, Bordeaux, Lyon, Marseille, Montpellier, Nice, Saint-Herblain, Strasbourg

2021-11-11

Recruiting

Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR

NCT04672525Prosthetic Infection

DrugsRifabutin·Rifampicin

Tourcoing Hospital

Phase 3

436

Amiens, Angers, Besançon, Béthune, Bordeaux, Boulogne-Billancourt, Brest, Caen

2021-11-08

Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

NCT05065216Acute Stroke, Ischemic Stroke, Stroke

DiaMedica Therapeutics Inc

Phase 2/3

728

Rennes, Bordeaux, Marseille, Nancy, Strasbourg

2021-11-07

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSutent·Savolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

Bordeaux, Quimper, Toulouse, Villejuif

2021-10-28

Active, closed

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin

AstraZeneca

Phase 3

454

Bordeaux, Dijon, Le Mans, Lyon, Marseille, Nantes, Toulouse, Villejuif

2021-10-28

Recruiting

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)

NCT04942080Myeloproliferative Neoplasm, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage, Primary Myelofibrosis, Fibrotic Stage

University Hospital, Angers

Not applicable

260

Angers, Bordeaux, Brest, Cholet, Le Mans, Morlaix, Paris, Poitiers

2021-10-28

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

430

Lyon, Bordeaux, Nantes, Saint-Herblain, Marseille, Paris, Villejuif

2021-10-25

Active, closed

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942Gastro-enteropancreatic Neuroendocrine Tumor

DrugsCAM2029·Octreotide LAR

Camurus AB

Phase 3

332

Bordeaux, Chambray-lès-Tours, Dijon, Lille, Lyon, Nantes, Rennes, Strasbourg

2021-10-22

Active, closed

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

NCT05198674Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases

Medtronic Vascular

Not applicable

1,899

Bordeaux, Paris

2021-10-20

Recruiting

Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET

NCT04954820Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor, Progressive Disease

DrugLutathera

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2

146

Angers, Bordeaux, Brest, Bron, Caen, Chambéry, Clermont-Ferrand, Clichy

2021-10-18

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

Bezannes, Bordeaux, Lille, Lyon, Montpellier, Plérin, Toulouse, Villejuif

2021-10-18

Active, closed

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

NCT04958239Neoplasms

DrugsEzabenlimab·Pembrolizumab

Boehringer Ingelheim

Phase 1

151

Bordeaux, Dijon, Saint-Herblain

2021-10-18

Active, closed

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse

DrugVimseltinib

Deciphera Pharmaceuticals, LLC

Phase 3

123

Bordeaux, Lyon, Villejuif

2021-10-14

Recruiting

Evaluation of the Efficiency of the Bone Substitute Cerament-G Locally Delivering Gentamicin in the Treatment of Chronic Osteomyelitis of Long Bones

NCT04805164Osteomyelitis Chronic

Hospices Civils de Lyon

Not applicable

220

Amiens, Besançon, Bordeaux, Boulogne-Billancourt, Brest, Caen, Lille, Lyon

2021-10-14

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 1

520

Bordeaux, Saint-Herblain, Nice, Lyon, Villejuif, Dijon, Paris

2021-10-13

Recruiting

Predictive Signature of Benralizumab Response

NCT04565483Asthma; Eosinophilic, Severe Asthma

DrugBenralizumab

Nantes University Hospital

Phase 4

220

Aix-en-Provence, Angers, Bordeaux, Brest, Dijon, Grenoble, Le Kremlin-Bicêtre, Le Mans

2021-10-11

Active, closed

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT04895696Systemic Lupus Erythematosus

Beeline Medicines Corporation

Phase 2

248

Pessac, Brest, Bordeaux, Caen, Lille, Marseille, Strasbourg

2021-10-11

Recruiting

Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode

NCT03646058Suicidal Ideation, Major Depressive Episode

DrugBuprenorphine

Centre Hospitalier Universitaire de Nīmes

Phase 3

180

Bordeaux, Le Kremlin-Bicêtre, Lyon, Nantes, Nîmes, Paris, Poitiers, Toulouse

2021-10-10

Active, closed

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

DrugsBosutinib·Asciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

405

Bordeaux, Lyon, Nantes, Paris

2021-10-06

Active, closed

Study of Lacutamab in Peripheral T-cell Lymphoma

NCT04984837Peripheral T Cell Lymphoma, Relapse/Recurrence

DrugsOxaliplatine·Gemcitabine

The Lymphoma Academic Research Organisation

Phase 2

Amiens, Angers, Avignon, Bayonne, Bordeaux, Caen, Chambéry, Clermont-Ferrand

2021-10-05

Recruiting

Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis

NCT04798651Multiple Sclerosis, Clinically Isolated Syndrome

DrugBlood sample

University Hospital, Bordeaux

Not applicable

150

Bordeaux

2021-09-30

Active, closed

Single-stage Surgery With Antibiotic-loaded Hydrogel Coated Implants Versus Two Stage Surgery for Secondary Prevention of Complex Chronic Periprosthetic Hip Joint Infection

NCT04251377Hip Prosthesis Infection

Centre Hospitalier Universitaire de Saint Etienne

Not applicable

Amiens, Bordeaux, Caen, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille

2021-09-30

Active, closed

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

NCT04603807Carcinoma, Non-Small-Cell Lung

DrugsEntrectinib·Crizotinib

Hoffmann-La Roche

Phase 3

217

Bordeaux, Lille, Lyon, Marseille, Rennes, Toulouse, Vantoux

2021-09-30

Active, closed

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer

DrugSabestomig

AstraZeneca

Phase 1/2

136

Bordeaux, Rennes, Villejuif

2021-09-28

Recruiting

Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening

NCT04949633Cervical Ripening, Unfavorable Cervix

DrugOxytocin

University Hospital, Tours

Phase 3

1,494

Angers, Bordeaux, Brest, Clermont-Ferrand, Marseille, Nancy, Nantes, Orléans

2021-09-28

Recruiting

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

NCT04837885Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour

University Hospital, Bordeaux

Phase 2

Bordeaux, Nîmes, Pessac, Toulouse

2021-09-24

Active, closed

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075Conventional Chondrosarcoma

DrugINBRX-109

Inhibrx Biosciences, Inc

Phase 2

206

Bordeaux, Lille, Lyon, Marseille, Montpellier, Nice, Paris, Rennes

2021-09-23

Active, closed

A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer

NCT04852653Rectal Cancer, Liquid Biopsy

University Hospital, Bordeaux

Observational

Bordeaux

2021-09-21

Active, closed

Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma

NCT04561492Multiple Myeloma

Drug[68Ga]Ga-PentixaFor

Nantes University Hospital

Phase 2

Bordeaux, Nantes, Paris

2021-09-21

Active, closed

Marshall Ethanolization, Pulmonary Vein Isolation and Line Completion for Ablation of Persistent Atrial Fibrillation

NCT04681872Atrial Fibrillation

University Hospital, Bordeaux

Not applicable

262

Bordeaux, Clermont-Ferrand, Neuilly-sur-Seine, Nîmes, Pessac, Saint-Denis, Toulouse

2021-09-20

Active, closed

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients

NCT04888312Metastatic Pancreatic Ductal Adenocarcinoma

DrugMitazalimab

Alligator Bioscience AB

Phase 1/2

Bordeaux, Lyon, Marseille, Paris, Vandœuvre-lès-Nancy

2021-09-17

Active, closed

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

NCT04776252HIV-1 Infection

DrugDOR/ISL

Merck Sharp & Dohme LLC

Phase 3

2,000

Nice, Dijon, Bordeaux, Toulouse, Rouen, Montpellier, Nantes, Tourcoing

2021-09-15

Active, closed

REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men

NCT04838769Benign Prostatic Hyperplasia (BPH)

Boston Scientific Corporation

Not applicable

155

Aix-en-Provence, Angers, Bordeaux, Grenoble, Lille, Lyon, Nice, Paris

2021-09-15

Recruiting

Cohort of Chronic Pain Patients

NCT04880096Chronic Pain

University Hospital, Clermont-Ferrand

Observational

5,000

Clermont-Ferrand, Boulogne-Billancourt, Paris, Amiens, Bayeux, Bordeaux, Bron, Grenoble

2021-09-14

Recruiting

Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor

NCT05937815Cystic Fibrosis

University Hospital, Bordeaux

Not applicable

253

Bordeaux, Grenoble, Lille, Limoges, Lyon, Marseille, Montpellier, Nancy

2021-09-13

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

689

Bordeaux, ClermontFerrand, Créteil, Lille, Lyon, Marseille, Montpellier, Paris

2021-09-13

Recruiting

Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma

NCT04460235Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin

Poitiers University Hospital

Phase 4

160

Angers, Bordeaux, Limoges, Nantes, Périgueux, Poitiers, Tours

2021-09-07

Active, closed

Diagnostic Performances of Preoperative Echo-guided Uterine Biopsy in the Management of Suspect Uterine Sarcoma Tumors (BIOPSAR)

NCT04250766Fibroid Uterus, Sarcoma Uterus

Institut Bergonié

Not applicable

Bordeaux

2021-09-07

Active, closed

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

NCT04994795Non-small Cell Lung Cancer Metastatic

Sophia Genetics SAS

Observational

4,000

Bobigny, Bordeaux, Boulogne-Billancourt, Lyon, Nantes, Paris, Suresnes, Toulon

2021-08-21

Active, closed

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

NCT05005975EPP, XLP

Tanabe Pharma America, Inc.

Phase 3

286

Bordeaux, Colombes, Nantes, Paris

2021-08-10

Active, closed

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

NCT04713514Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer

DrugsTedopi·Keytruda·Pembrolizumab

ARCAGY/ GINECO GROUP

Phase 2

180

Angers, Avignon, Bayonne, Besançon, Bordeaux, Caen, Chambray-lès-Tours, Cholet

2021-08-05

Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma

Pierre Fabre Medicament

Phase 1

400

Bordeaux, Caen, Lille, Lyon, Marseille, Nantes, Nice, Paris

2021-08-04

Recruiting

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

NCT04602377Small Cell Ovarian Carcinoma

DrugsKeytruda·Pembrolizumab

ARCAGY/ GINECO GROUP

Phase 2

Angers, Besançon, Bordeaux, Dijon, Lille, Limoges, Lyon, Montpellier

2021-08-04

Recruiting

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT04939610Solid Tumor

Drug177Lu-FAP-2286

Novartis Pharmaceuticals

Phase 1/2

222

Montpellier, Bordeaux, Clermont-Ferrand, Marseille, Vandœuvre-lès-Nancy

2021-07-30

Recruiting

Lung Cancer Screening in a Population Exposed to Occupational Lung Carcinogens

NCT03562052Lung Cancer

Centre Hospitalier Intercommunal Creteil

Observational

6,000

Bordeaux, Brest, Caen, Créteil, Rennes, Rouen, Toulon

2021-07-22

Recruiting

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

NCT04877288Renal Allograft Recipients

DrugsCyclosporine A·Belatacept·Mycophenolate Mofetil·Tacrolimus

Bristol-Myers Squibb

Phase 3

102

Nantes, Bordeaux, Bron, Marseille, Paris

2021-07-21

Recruiting

Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

NCT04698785Bone Sarcoma, Osteosarcoma

Centre Leon Berard

Phase 2

Besançon, Bordeaux, Dijon, Lille, Lyon, Marseille, Montpellier, Nantes

2021-07-21

Active, closed

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms

DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed

Eli Lilly and Company

Phase 1/2

540

Bordeaux, Lyon, Montpellier, Toulouse, Villejuif

2021-07-19

Active, closed

Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

NCT04870203Rheumatoid Arthritis

University Hospital, Bordeaux

Phase 3

160

Bayonne, Belfort, Bobigny, Bordeaux, Brest, Caluire-et-Cuire, Clermont-Ferrand, Dax

2021-07-15

Active, closed

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

NCT04657289Neovascular Age-related Macular Degeneration (nAMD)

DrugRanibizumab

Hoffmann-La Roche

Phase 3

451

Bordeaux, Lyon, Marseille, Paris

2021-07-14

Recruiting

Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform

NCT04927156Intracranial Aneurysm, Brain Arterial Disease, Acute Ischemic Stroke, Peripheral Vascular Diseases

Balt Extrusion

Observational

10,000

Angers, Bordeaux, La Tronche, Lille, Paris, Tours

2021-07-12

Active, closed

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

NCT04857034Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 2

Bordeaux, Créteil, Paris

2021-07-12

Recruiting

Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment.

NCT07606508Cutaneous Squamous Cell Carcinoma (CSCC)

University Hospital, Lille

Observational

1,500

Amiens, Annecy, Besançon, Blois, Bobigny, Bordeaux, Boulogne-Billancourt, Caen

2021-07-09

Recruiting

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

NCT04803994Hepatocellular Carcinoma

DrugsTecentriq·Avastin·Atezolizumab·Bevacizumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 3

434

Avignon, Bobigny, Bordeaux, Clermont-Ferrand, Clichy, Grenoble, Lyon, Marseille

2021-07-06

Active, closed

Safety and Performance of the SPINEVISION Hexanium ACIF in the Treatment of Cervical Spine Degenerative Disc Disease

NCT06155409Intervertebral Disc Degeneration

SPINEVISION SAS

Observational

148

Bordeaux, Le Port-Marly, Nancy, Périgueux, Vantoux

2021-07-06

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Avignon, Bordeaux, Caen, Dijon, Marseille, Montpellier, Pierre-Bénite, Rouen

2021-06-28

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfox

Mirati Therapeutics Inc.

Phase 3

461

Chambray-lès-Tours, Avignon, Besançon, Bordeaux, Brest, Dijon, Lille, Lyon

2021-06-24

Active, closed

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

469

Angers, Bordeaux, Clermont-Ferrand, Lyon, Paris, Villejuif

2021-06-15

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 October 2026. https://priyalifescience.com/clinical-trials-france/city/bordeaux?page=2

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,697 studies in total at the last sync on 26 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,389 of those studies with a site in Bordeaux.

How many clinical trials are recruiting in Bordeaux?

755 of the 1,389 studies on this page are recruiting new participants as of the 26 Oct 2026, 03:20 UTC sync. A further 110 have not yet opened recruitment, 515 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.